



# health

Department:  
Health  
REPUBLIC OF SOUTH AFRICA

Private Bag X828, PRETORIA, 0001. Civitas Building Cnr Thabo Sehume & Struben Streets, PRETORIA 0001  
Directorate: Affordable Medicines, Tel: (012) 395 8530 Fax: (012) 395 8823/4

Enquiries: [tenders@health.gov.za](mailto:tenders@health.gov.za)

Ref: **HP06-2021SVP**

**HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND  
INSULIN DEVICES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD  
01 MAY 2021 TO 30 APRIL 2024**

1. The attached contract circular is for your information.
2. This contract will be subject to the General Conditions of Contract issued in accordance with Chapter 16A of the Treasury Regulations published in terms of the Public Finance Management Act, 1999 (Act 1 of 1999). The Special Requirements and Conditions of Contract are supplementary to the General Conditions of Contract. Where, however, the Special Requirements and Conditions of Contract are in conflict with the General Conditions of the Contract, the Special Requirements and Conditions of Contract will prevail.
3. The bid price offered applies to the product specified e.g. price per single unit, as per specification.
4. The following provincial Departments of Health will participate in this contract:

| PARTICIPANTS  | CONTACT PERSON | TEL NO         | E-MAIL                             |
|---------------|----------------|----------------|------------------------------------|
| Eastern Cape  | Mr C Dlova     | (047) 532-5536 | mncedisi.dlova@ehealth.gov.za      |
| Free State    | Ms M Smits     | (051) 411-0525 | SmitsM1@fshealth.gov.za            |
| Gauteng       | Mr DS Malele   | (011) 628-9131 | dumisane.malele@gauteng.gov.za     |
| Kwazulu-Natal | MS SB Nhlapo   | (035) 901-7004 | sibusisiwe.nhlapo@kznhealth.gov.za |
| Limpopo       | Mr TS Rasekele | (015) 223-9065 | rassolly@gmail.com                 |
| Mpumalanga    | Mr T Moralo    | (013) 283-9001 | tshegofatsom@mpuhealth.gov.za      |
| North West    | Mr M Gutta     | (018) 384-4838 | mgutta@nwpg.gov.za                 |
| Northern Cape | Ms E Delpport  | (053) 830-2717 | edelpport@ncpg.gov.za              |
| Western Cape  | Mr N Mia       | (021) 483-5800 | nisaar.mia@westerncape.gov.za      |

**K JAMALOODIEN**  
**DIRECTOR: AFFORDABLE MEDICINES**  
**For: DIRECTOR-GENERAL: HEALTH**  
**DATE: 29 March 2021**

## 1. IMPORTANT GENERAL INFORMATION

- 1.1 Please note that two supplier codes are listed for each supplier. This is to provide for the required supplier registration on the Central Supplier Database (CSD) at National Treasury.
- 1.2 Please note that the delivered price is for the unit of measure (UOM) offered. Unit of Measure, National Stock Numbers and prices should be carefully matched when placing or executing orders.
- 1.3 All prices are inclusive of 15 % VAT.
- 1.4 All prices are on a delivered basis.
- 1.5 Contact persons and e-mail addresses indicated hereunder are to be used for contract enquiries and not for orders.

## 2. NAMES AND ADDRESSES OF CONTRACTORS AND CONTACT DETAIL

| Supplier Name                              | Supplier Code | CSD Code    | Postal Address   | Contact Person   | Telephone / Cellphone Number     | E-mail                            |
|--|---------------|-------------|--|------------------|----------------------------------|-----------------------------------|
| Abbott Laboratories South Africa (Pty) Ltd | V2150         | MAAA0030395 | 219 Golf Club Terrace<br><b>CONSTANTIA KLOOF</b><br>1709 | Maxine Smith     | (011) 858-2379<br>(060) 579-7944 | maxine.smith@abbott.com           |
| AbbVie (Pty) Ltd                           | V3PG3         | MAAA0076921 | P O Box 4840<br><b>WELTEVREDEN PARK</b><br>1709          | Sarona Radley    | (011) 831-3200<br>(060) 348-9941 | sarona.radley@abbvie.com          |
| Accord Healthcare (Pty) Ltd                | V2MB8         | MAAA0005335 | Private Bag X51<br><b>RIVONIA</b><br>2128                | Reslan Nagoor    | (011) 234-5703<br>(082) 494-2510 | reshlan.nagoor@accordhealth.co.za |
| Actor Pharma (Pty) Ltd                     | V2G28         | MAAA0183044 | P O Box 7408<br><b>HALFWAY HOUSE</b><br>1685             | Malcolm Blane s  | (011) 312-3812<br>(082) 551-4010 | malcolmb@actorpharma.co.za        |
| Adcock Ingram Critical Care (Pty) Ltd      | V4222         | MAAA0010153 | P O Box 6888<br><b>JOHANNESBURG</b><br>2000              | Vusani Matshidza | (011) 494-8129<br>(079) 894-7873 | criticalcare.tenders@adcock.com   |

| Supplier Name                            | Supplier Code | CSD Code    | Postal Address   | Contact Person      | Telephone / Cellphone Number     | E-mail  |
|--|---------------|-------------|--|---------------------|----------------------------------|---|
| Adcock Ingram Healthcare (Pty) Ltd       | V2272         | MAAA0036413 | Private Bag X69<br><b>BRYANSTON</b><br>2021  | Nkosinathi.Mthethwa | (011) 635-0103<br>(072) 328-1179 | nkosinathi.mthethwa@adcock.com                |
| Ascendis Pharma (Pty) Ltd                | V0DM6         | MAAA0043637 | Postnet Suite #252<br>Private Bag X21<br><b>BRYANSTON</b><br>2021                          | Marnus Sonnekus     | (011) 036-9600<br>(082) 329-8225 | marnus.sonnekus@ascendishealth.com            |
| B Braun Medical (Pty) Ltd                | VYL89         | MAAA0040832 | P O Box 1787<br><b>RANDBURG</b><br>2125  | Walda Van Zyl       | (010) 222-3000<br>(073) 494-8695 | walda.van_zyl@bbraun.com                      |
| Biotech Laboratories (Pty) Ltd           | VUV35         | MAAA0029826 | Private Bag X65<br><b>HALFWAY HOUSE</b><br>1685  | Faried Dean         | (011) 848-3050<br>(082) 455-1149 | tenders@biotechlabs.co.za                     |
| Equity Pharmaceuticals (Pty) Ltd         | V1QZ3         | MAAA0007480 | 100 Sovereign Drive<br>Route 21, Corporate Park<br>Nelmapius Drive<br><b>IRENE</b><br>0157 | Carel Bouwer        | (012) 345-1747<br>(082) 879-8866 | carel@equitypharma.co.za                      |
| Ferring (Pty) Ltd                        | VXY92         | MAAA0005879 | Route 21, Corporate Park<br>6 Regency Drive<br><b>IRENE</b><br>0157                        | Martha van Zyl      | (012) 443-4307<br>(082) 565-2656 | mvz@ferring.com<br>merciam.vanzyl@ferring.com |
| Lundbeck SA (Pty) Ltd                    | VVS90         | MAAA0031052 | P O Box 2171<br><b>NORTHRIDING</b><br>2162   | Julianne Howarth    | (011) 699-1600<br>(078) 800-3843 | jhl@lundbeck.com                              |
| Litha Pharma (Pty) Ltd<br>(Acino Pharma) | VGS73         | MAAA0009244 | P O Box 8356<br><b>MIDRAND</b><br>1685   | Anand Reddy         | (011) 516-1700<br>(066) 304-6900 | state_za@acino.swiss                          |

| Supplier Name                         | Supplier Code | CSD Code    | Postal Address  | Contact Person              | Telephone / Cellphone Number     | E-mail                          |
|---------------------------------------|---------------|-------------|---|-----------------------------|----------------------------------|---------------------------------|
| Macleods Pharmaceuticals SA (Pty) Ltd | V3PJ1         | MAAA0007167 | Office Block 1, Bassonia Estate Office Park (East)<br>1 Cussonia Drive<br>Bassonia Rock Ext 12<br><b>ALBERTON</b><br>2061 | Vanita Rajool               | (011) 628-1169<br>(083) 266-9223 | vanitar@macleodspharma.com      |
| Mylan (Pty) Ltd                       | V3PS6         | MAAA0081441 | Postnet Suite X23<br>Private Bag X10010<br><b>EDENVALE</b><br>1610  | Kumaraswamy Ekhambaram      | (011) 451-1300<br>(071) 473-3900 | kumaraswamy.ekhambaram@mylan.in |
| Novartis SA (Pty) Ltd                 | VBVW2         | MAAA0006317 | Magula Crescent West,<br>Waterfall City<br>Lukskei Vlei<br><b>MIDRAND</b><br>2090   | Masego Masipa               | (011) 347-6600<br>(082) 805-1262 | masego.masipa@novartis.com      |
| Novo Nordisk (Pty) Ltd                | V2743         | MAAA0013414 | P O Box 783155<br><b>SANDTON</b><br>2146  | Venkata Kalyan Papa Konduri | (011) 202-0500<br>(079) 694-1953 | tsmk@novonordisk.com            |
| P & G South African Trading (Pty) Ltd | VJDY7         | MAAA0913191 | Private Bag X10062<br><b>SANDTON</b><br>2196  | Deon Labuschagne            | (010) 001-9650<br>(082) 897-3611 | labuschagne.d@pg.com            |
| Pfizer Laboratories (Pty) Ltd         | V2189         | MAAA0019202 | 85 Bute Lane<br><b>SANDTON</b><br>2146  | Themba Mnguni               | (011) 320-6091<br>(082) 307-9658 | themba.mnguni@pfizer.com        |
| Pharmacare Limited                    | V2205         | MAAA0008452 | P O Box 1587<br><b>GALLO MANOR</b><br>2052  | Itumeleng Mathe             | (011) 239-6243<br>(083) 298-4366 | imathe@aspenpharma.com          |

| Supplier Name                      | Supplier Code | CSD Code    | Postal Address                                  | Contact Person    | Telephone / Cellphone Number      | E-mail                          |
|------------------------------------|---------------|-------------|---|-------------------|-----------------------------------|---------------------------------|
| Pharmaco Distribution (Pty) Ltd    | VBVW1         | MAAA0044115 | P O Box 786522<br><b>SANDTON</b><br>2146        | Jan van den Berg  | (011) 784-0077<br>(082) 572-7832  | jan.vandenberg@pharmaco.co.za   |
| Pharma-Q (Pty) Ltd                 | V1NK1         | MAAA0016762 | Private Bag X09<br><b>FLORIDA</b><br>1710       | Anand Mehta       | (011) 247-1600<br>(083) 636-4444  | andy@pharmaq.co.za              |
| Piramal Critical Care SA (Pty) Ltd | VFPD3         | MAAA0655823 | P O Box 1088<br><b>CRESTA</b><br>2188           | Divya Ranchod     | (011) 678-1948<br>(082) 454-1781  | divya.ranchod@piramal.com       |
| Ranbaxy Pharmaceuticals (Pty) Ltd  | V4728         | MAAA0000384 | P O Box 43486<br><b>INDUSTRIA</b><br>2042       | Deepakh Sewnarain | (012) 643-2000<br>(082) 893-8649  | deepakh.sewnarain@sunpharma.com |
| Sandoz SA (Pty) Ltd                | VVZ69         | MAAA0011663 | P O Box 12257<br><b>VORNA VALLEY</b><br>1686    | Renee Moodley     | (011) 545-0424<br>(083) 704-1806  | renee.moodley@sandoz.com        |
| Sanofi-Aventis SA (Pty) Ltd        | V2160         | MAAA0009069 | Private Bag X207<br><b>MIDRAND</b><br>1685      | Jaidev Maharaj    | (011) 847-5264<br>(082) 943-3952  | jaidev.maharaj@sanofi.com       |
| Specpharm (Pty) Ltd.               | V3EQ1         | MAAA0009737 | P O Box 651<br><b>HALFWAY HOUSE</b><br>1685     | Gregory Hill      | (011) 652-0465<br>(073) 676-0775  | ghill@specpharm.co.za           |
| Unimed Healthcare (Pty) Ltd        | V92D6         | MAAA0444639 | Private Bag X12<br><b>PRETORIA WEST</b><br>0117 | Arshad Bera       | (011) 056- 6999<br>(083) 647-7860 | arshad@unimedhealthcare.co.za   |

AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH

| Item No | Item Specification  | Estimate  | Quantity Awarded | Split | Supplier Name                         | Central Supplier Database Number | Supplier Code V-Number | Registered Product Name                         | Delivered Price | Pack Size Offered: Unit Pack | Lead-Time (≤ 14 calendar days) | MOQ          | Total Score | National Stock Number | UOM       |    |
|---------|---|-----------|------------------|-------|---------------------------------------|----------------------------------|------------------------|---|-----------------|------------------------------|--------------------------------|--------------|-------------|-----------------------|-----------|----|
| 1       | Acetylcysteine 200mg/ml, injection, 10ml  |           | 213 295          |       | Equity Pharmaceuticals (Pty) Ltd      | MAAA0007480                      | V1QZ3                  | Paradote  | R196.00         | 1 x 10 vials                 | 14                             | 1 x 10 vials | 91.00       | 181915188             | VI        |    |
| 2       | Adenosine 3mg/ml, injection, 2ml  |           | 74 740           |       | Sanofi-Aventis SA (Pty) Ltd           | MAAA0009069                      | V2160                  | ADENOCOR VIALS 6MG / 2ML 6                      | R156.21         | 1 x 1                        | 14                             | 6            | 91.00       | 180373081             | VI        |    |
| 3       | Adrenaline (Epinephrine) 0.15mg/0.3ml, auto-injection, 0.3ml  |           | 5 570            |       | Mylan (Pty) Ltd                       | MAAA0081441                      | V3PS6                  | EPIPEN JUNOR AUTO-INJECTOR                      | R760.00         | 1 x 1                        | 14                             | 10           | 93.00       | 222000173             | EA        |    |
| 4       | Adrenaline (Epinephrine) 0.3mg/0.3ml, auto-injection, 0.3ml   |           | 2 336            |       | Mylan (Pty) Ltd                       | MAAA0081441                      | V3PS6                  | EPIPEN  | R749.00         | 1 x 1                        | 14                             | 10           | 93.00       | 222000174             | EA        |    |
| 5       | Adrenaline (Epinephrine) 1mg/ml, injection, 1ml   | 7 520 710 | 6 768 639        | 90%   | Pharma-Q (Pty) Ltd                    | MAAA0016762                      | V1NK1                  | Pharma-Q Adrenaline Inj 1mg/1ml                 | R4.00           | 1 x 10                       | 14                             | 500          | 96.00       | 180075485             | AM        |    |
| 5       | Adrenaline (Epinephrine) 1mg/ml, injection, 1ml   | 7 520 710 | 752 071          | 10%   | TO FOLLOW                             |                                  |                        |   |                 |                              |                                |              |             |                       | 180075485 | AM |
| 6       | Alfentanil 0.5mg/ml, injection, 2ml   |           | 119 310          |       | Piramal Critical Care SA (Pty) Ltd    | MAAA0655823                      | VFPD3                  | Rapifen 2ml                                     | R49.83          | 5 x 2ml amps                 | 14                             | 5 x 2ml amps | 90.00       | 180075489             | AM        |    |
| 7       | Alprostadil 0.5mg/ml, injection, 1ml<br><br>Product awarded:<br>Alprostadil 0.5mg/ml, injection, 1ml<br>1 pack of 5 injections<br><br>Price vs Pack size:<br>1 x 1 injection = R2,744.60<br>1 x 5 injections = R13,723.09 |           | 6 250            |       | Pfizer Laboratories (Pty) Ltd         | MAAA0019202                      | V2189                  | PROSTIN VR                                      | R2 744.60       | 1 x 5                        | 14                             | 5            | 91.00       | 180075498             | AM        |    |
| 9       | Aminophylline 25mg/ml, injection, 10ml  |           | 354 560          |       | Adcock Ingram Critical Care (Pty) Ltd | MAAA0010153                      | V4222                  | Sabax Aminophylline IV                          | R3.57           | 1 x 10 vials                 | 14                             | 10           | 99.87       | 189700102             | AM        |    |
| 10      | Amiodarone 50mg/ml, injection, 3ml  |           | 223 660          |       | Sanofi-Aventis SA (Pty) Ltd           | MAAA0009069                      | V2160                  | CORDARONE X IV 150MG/3ML 6                      | R61.09          | 1 x 1                        | 14                             | 6            | 91.00       | 180075509             | AM        |    |
| 11      | Atracurium 10mg/ml, injection, 2.5ml  |           | 81 270           |       | Pharmacare Limited                    | MAAA0008452                      | V2205                  | Tracrium Inj 5x2.5ml                            | R78.66          | 5 x 2.5ml                    | 14                             | 5            | 95.00       | 180075518             | AM        |    |
| 12      | Atracurium 10mg/ml, injection, 5ml  |           | 58 400           |       | Pharmacare Limited                    | MAAA0008452                      | V2205                  | Tracrium Inj 5x5ml                              | R158.41         | 5 x 5ml                      | 14                             | 5            | 95.00       | 180075520             | AM        |    |
| 13      | Atropine 0.5mg/ml, injection, 1ml   | 1 278 840 | 1 023 072        | 80%   | Pharma-Q (Pty) Ltd                    | MAAA0016762                      | V1NK1                  | Pharma-Q Atropine Inj. 0.5mg/1ml                | R4.00           | 1 x 10                       | 14                             | 500          | 96.00       | 189707023             | AM        |    |
| 13      | Atropine 0.5mg/ml, injection, 1ml   | 1 278 840 | 255 768          | 20%   | TO FOLLOW                             |                                  |                        |   |                 |                              |                                |              |             |                       |           |    |
| 14      | Atropine 1mg injection, 1ml   | 2 353 110 | 1 882 488        | 80%   | Pharma-Q (Pty) Ltd                    | MAAA0016762                      | V1NK1                  | Pharma-Q Atropine Inj. 1mg/1ml                  | R4.20           | 1 x 10                       | 14                             | 400          | 96.00       | 189707024             | AM        |    |
| 14      | Atropine 1mg injection, 1ml   | 2 353 110 | 470 622          | 20%   | TO FOLLOW                             |                                  |                        |   |                 |                              |                                |              |             |                       |           |    |
| 15      | Betamethasone 4mg/ml, injection, 1ml  |           | 1 199 860        |       | Pharma-Q (Pty) Ltd                    | MAAA0016762                      | V1NK1                  | Pharma-Q Betamethasone 4mg/1ml                  | R4.75           | 1 x 10                       | 14                             | 400          | 96.00       | 180075545             | AM        |    |
| 16      | Biperiden 5mg, injection, 1ml   |           | 63 180           |       | Pharmaco Distribution (Pty) Ltd       | MAAA0044115                      | VBVW1                  | AKINETON  | R45.17          | 1 x 5                        | 14                             | 5            | 90.00       | 180075548             | AM        |    |
| 17      | Bupivacaine 5mg, Adrenaline 5mcg/ml, injection, 20ml  |           | 292 780          |       | Adcock Ingram Critical Care (Pty) Ltd | MAAA0010153                      | V4222                  | MACAINE HCL 0.5% INJECTION WITH ADRENALINE      | R31.05          | 1 x 10 vials                 | 14                             | 10           | 100.00      | 180075555             | AM        |    |
| 18      | Bupivacaine 5mg, Dextrose Anhydrous 72.7mg/ml, injection, 4ml   |           | 974 370          |       | Adcock Ingram Critical Care (Pty) Ltd | MAAA0010153                      | V4222                  | MACAINE HCL 0.5% SPINAL INJECTION WITH DEXTROSE | R4.60           | 1 x 10                       | 14                             | 10           | 100.00      | 180075556             | AM        |    |
| 19      | Bupivacaine 5mg/ml injection, spinal, 4ml   |           | 206 140          |       | Adcock Ingram Critical Care (Pty) Ltd | MAAA0010153                      | V4222                  | MACAINE HCL 0.5% SPINAL INJECTION               | R16.68          | 1 x 10                       | 14                             | 10           | 100.00      | 180075553             | AM        |    |
| 20      | Bupivacaine 5mg/ml, injection, 10ml   |           | 971 660          |       | Adcock Ingram Critical Care (Pty) Ltd | MAAA0010153                      | V4222                  | MACAINE HCL 0.5% INJECTION                      | R6.90           | 1 x 10                       | 14                             | 10           | 100.00      | 180075551             | AM        |    |

AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH

| Item No | Item Specification   | Estimate  | Quantity Awarded | Split | Supplier Name                   | Central Supplier Database Number | Supplier Code V-Number | Registered Product Name                       | Delivered Price | Pack Size Offered: Unit Pack | Lead-Time (≤ 14 calendar days) | MOQ                                | Total Score | National Stock Number | UOM       |    |
|---------|--|-----------|------------------|-------|---------------------------------|----------------------------------|------------------------|---|-----------------|------------------------------|--------------------------------|------------------------------------|-------------|-----------------------|-----------|----|
| 22      | Calcium gluconate 10% m/v, injection, 10ml   |           | 754 340          |       | TO FOLLOW                       |                                  |                        |   |                 |                              |                                |                                    |             |                       | 180075565 | AM |
| 23      | Cisatracurium 2mg/ml, injection, 2.5 ml  | 266 650   | 239 985          | 90%   | Accord Healthcare (Pty) Ltd     | MAAA0005335                      | V2MB8                  | Cistrax 5mg/2.5ml                             | R25.30          | 1 x 5                        | 14                             | 20                                 | 91.00       | 181767288             | AM        |    |
| 23      | Cisatracurium 2mg/ml, injection, 2.5 ml  | 266 650   | 26 665           | 10%   | TO FOLLOW                       |                                  |                        |   |                 |                              |                                |                                    |             |                       |           |    |
| 24      | Cisatracurium 2mg/ml, injection, 5ml   | 237 390   | 166 173          | 70%   | Accord Healthcare (Pty) Ltd     | MAAA0005335                      | V2MB8                  | Cistrax 10mg/5ml                              | R37.95          | 1 x 5                        | 14                             | 20                                 | 91.00       | 180308024             | AM        |    |
| 24      | Cisatracurium 2mg/ml, injection, 5ml   | 237 390   | 71 217           | 30%   | TO FOLLOW                       |                                  |                        |   |                 |                              |                                |                                    |             |                       |           |    |
| 26      | Clotiapine 10mg/ml, injection, 4ml   |           | 78 395           |       | Pharmaco Distribution (Pty) Ltd | MAAA0044115                      | VBVW1                  | ETOMINE                                       | R28.72          | 1 x 10                       | 14                             | 10                                 | 90.00       | 180075729             | AM        |    |
| 29      | Desmopressin 4mcg, injection, 1ml  |           | 9 660            |       | Ferring (Pty) Ltd               | MAAA0005879                      | VXY92                  | DDAVP INJECTION 4MCG/ML 1ML                   | R97.95          | 1 x 10 ampoules per pack     | 14                             | 5 x 10 ampoules pack (50 ampoules) | 90.00       | 180075757             | AM        |    |
| 30      | Dexamethasone 4mg, injection, 1ml  | 5 270 300 | 4 743 270        | 90%   | Pharma-Q (Pty) Ltd              | MAAA0016762                      | V1NK1                  | Pharma-Q Dexamethasone Phosphate Inj. 4mg/1ml | R5.40           | 1 x 10                       | 14                             | 400                                | 96.00       | 180075759             | AM        |    |
| 30      | Dexamethasone 4mg, injection, 1ml  | 5 270 300 | 527 030          | 10%   | TO FOLLOW                       |                                  |                        |   |                 |                              |                                |                                    |             |                       |           |    |
| 31      | Dexmedetomidine, 100 mcg/ml, Injection for infusion, 2ml<br><b>Product awarded:</b><br>Dexmedetomidine, 100 mcg/ml, Injection for infusion, 2ml<br>1 pack of 5 injections<br><br><b>Price vs Pack size:</b><br>1 x 1 injection = R510.82<br>1 x 5 injections = R2,554.10 |           | 58 320           |       | Pfizer Laboratories (Pty) Ltd   | MAAA0019202                      | V2189                  | PreceDEX                                      | R510.82         | 1 x 5                        | 14                             | 5                                  | 91.00       | 181937349             | AM        |    |
| 32      | Dextrose 50% m/v, injection, 20ml  |           | 1 293 980        |       | TO FOLLOW                       |                                  |                        |   |                 |                              |                                |                                    |             |                       | 180075794 | AM |
| 33      | Dextrose 50% m/v, injection, 50ml  |           | 1 140 740        |       | TO FOLLOW                       |                                  |                        |   |                 |                              |                                |                                    |             |                       | 180352804 | BG |
| 34      | Diazepam 5mg/ml, injection, 2ml  |           | 771 330          |       | Pharma-Q (Pty) Ltd              | MAAA0016762                      | V1NK1                  | Pharma-Q Diazepam Inj. 10mg/2ml               | R4.00           | 1 x 10                       | 14                             | 400                                | 96.00       | 180075798             | AM        |    |
| 35      | Diclofenac 25mg/ml, injection, 3ml   | 8 327 390 | 6 661 912        | 80%   | Unimed Healthcare (Pty) Ltd     | MAAA0444639                      | V92D6                  | Diclofenac Injection Unimed                   | R1.52           | 1 x 50                       | 14                             | 750                                | 100.00      | 180075799             | AM        |    |
|         |  |           | 1 665 478        | 20%   | Pharma-Q (Pty) Ltd              | MAAA0016762                      | V1NK1                  | Dicon 75 inj                                  | R1.65           | 1 x 50                       | 14                             | 500                                | 88.30       |                       |           |    |
| 36      | Digoxin 0,25mg/ml, injection, 2ml  |           | 39 280           |       | Pharmacare Limited              | MAAA0008452                      | V2205                  | Lanoxin 0.5mg Inj 5 x 2ml                     | R21.39          | 5 x 2ml                      | 14                             | 5                                  | 95.00       | 180075803             | AM        |    |
| 38      | Dobutamine 12.5mg/ml, injection, 20ml  |           | 206 440          |       | TO FOLLOW                       |                                  |                        |   |                 |                              |                                |                                    |             |                       | 189715235 | VI |
| 39      | Dopamine 40mg/ml, injection, 5ml   |           | 106 755          |       | Pharma-Q (Pty) Ltd              | MAAA0016762                      | V1NK1                  | Pharma-Q Dopamine Concentrate Inj. 200mg/5ml  | R7.80           | 1 x 10                       | 14                             | 250                                | 96.00       | 180075879             | AM        |    |
| 40      | Enoxaparin 40mg, injection, 0.4ml  |           | 8 663 680        |       | Sanofi-Aventis SA (Pty) Ltd     | MAAA0009069                      | V2160                  | CLEXANE PF SYRINGE 40mg 10 X 0.4ML            | R53.61          | 1 x 1                        | 14                             | 10                                 | 91.00       | 180077964             | SG        |    |
| 41      | Enoxaparin 60mg, injection, 0.6ml  |           | 901 800          |       | Sanofi-Aventis SA (Pty) Ltd     | MAAA0009069                      | V2160                  | CLEXANE PF SYRINGE 60mg 10 X 0.6ML            | R67.49          | 1 x 1                        | 14                             | 10                                 | 91.00       | 222000901             | SG        |    |
| 42      | Enoxaparin 80mg, injection, 0.8ml  |           | 2 019 230        |       | Sanofi-Aventis SA (Pty) Ltd     | MAAA0009069                      | V2160                  | CLEXANE PF SYRINGE 80mg 10 X 0.8ML            | R81.50          | 1 x 1                        | 14                             | 10                                 | 91.00       | 180970533             | EA        |    |

## AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH

| Item No | Item Specification  | Estimate  | Quantity Awarded | Split | Supplier Name                         | Central Supplier Database Number | Supplier Code V-Number | Registered Product Name                      | Delivered Price | Pack Size Offered: Unit Pack | Lead-Time (≤ 14 calendar days) | MOQ           | Total Score | National Stock Number | UOM       |    |
|---------|---|-----------|------------------|-------|---------------------------------------|----------------------------------|------------------------|--|-----------------|------------------------------|--------------------------------|---------------|-------------|-----------------------|-----------|----|
| 50      | Etomidate 2mg/ml, injection, 10ml   |           | 145 080          |       | Piramal Critical Care SA (Pty) Ltd    | MAAA0655823                      | VFPD3                  | Hypnomidate                                  | R36.74          | 5 x 10ml amps                | 14                             | 5 x 10ml amps | 90.00       | 180075956             | AM        |    |
| 51      | Fentanyl 0.05mg/ml, injection, 2ml  | 1 581 570 | 1 423 413        | 90%   | Pharma-Q (Pty) Ltd                    | MAAA0016762                      | V1NK1                  | Pharma-Q Fentanyl Inj. 100ug/2ml             | R4.70           | 1 x 10                       | 14                             | 400           | 96.00       | 180075959             | AM        |    |
| 51      | Fentanyl 0.05mg/ml, injection, 2ml  | 1 581 570 | 158 157          | 10%   | TO FOLLOW                             |                                  |                        |  |                 |                              |                                |               |             |                       | 180075959 | AM |
| 52      | Fentanyl 0.05mg/ml, injection, 10ml   |           | 370 850          |       | Pharma-Q (Pty) Ltd                    | MAAA0016762                      | V1NK1                  | Pharma-Q Fentanyl Inj. 500ug/10ml            | R10.20          | 1 x 10                       | 14                             | 200           | 96.00       | 180075960             | AM        |    |
| 54      | Flupenthixol decanoate 20mg/ml, injection, 1ml  |           | 1 507 530        |       | Lundbeck SA (Pty) Ltd                 | MAAA0031052                      | VVS90                  | Fluanxol Depot 20 mg/ml                      | R36.06          | 1 x 1                        | 14                             | 5             | 90.00       | 180017761             | AM        |    |
| 55      | Furosemide 10mg/ml, injection, 25ml   |           | 245 280          |       | TO FOLLOW                             |                                  |                        |  |                 |                              |                                |               |             |                       | 180075988 | AM |
| 56      | Furosemide 10mg/ml, injection, 2ml  |           | 7 085 900        |       | Adcock Ingram Critical Care (Pty) Ltd | MAAA0010153                      | V4222                  | ADCO FUROSEMIDE 20MG/2ML                     | R2.97           | 1 x 10 vials                 | 14                             | 10            | 100.00      | 180075982             | AM        |    |
| 57      | Furosemide 10mg/ml, injection, 5ml  |           | 342 230          |       | Pharma-Q (Pty) Ltd                    | MAAA0016762                      | V1NK1                  | Pharma-Q Furosemide Inj. 50mg/5ml            | R5.55           | 1 x 10                       | 14                             | 300           | 96.00       | 180075985             | AM        |    |
| 58      | Glucagon 1mg, injection, 1ml  |           | 30 050           |       | Novo Nordisk (Pty) Ltd                | MAAA0013414                      | V2743                  | GLUCAGEN HYPOKIT                             | R394.98         | 1 x 1                        | 14                             | 1             | 92.00       | 180309135             | VI        |    |
| 60      | Glycopyrronium bromide 0.2mg/ml, injection, 2ml   |           | 622 200          |       | Pharmacare Limited                    | MAAA0008452                      | V2205                  | Robinul Inj 2ml                              | R12.84          | 10 x 2ml                     | 14                             | 10            | 95.00       | 180075998             | AM        |    |
| 65      | Hydrocortisone 100mg/2ml, injection, 2ml  | 4 166 740 | 3 750 066        | 90%   | Macleods Pharmaceuticals SA (Pty) Ltd | MAAA0007167                      | V3PJ1                  | Macleods Hydrocortisone Injection            | R17.37          | 1 x 2ml                      | 14                             | 100           | 95.00       | 180018040             | VI        |    |
| 65      | Hydrocortisone 100mg/2ml, injection, 2ml<br><b>Product awarded:</b><br>Hydrocortisone 100mg/2ml, injection, 2ml<br>1 pack of 5 injections<br><br><b>Price vs Pack size:</b><br>1 x 1 injection = R39.34<br>1 x 5 injections = R196.70 | 4 166 740 | 416 674          | 10%   | Pfizer Laboratories (Pty) Ltd         | MAAA0019202                      | V2189                  | SOLU-CORTEF 100mg                            | R39.34          | 1 x 5                        | 14                             | 5             | -22.83      | 180018040             | VI        |    |
| 66      | Hyoscine Butylbromide 20mg, injection, 1ml  |           | 2 338 110        |       | Pharma-Q (Pty) Ltd                    | MAAA0016762                      | V1NK1                  | Pharma-Q Hyoscine Butylbromide Inj. 20mg/1ml | R5.30           | 1 x 10                       | 14                             | 300           | 96.00       | 180076081             | AM        |    |
| 67      | Insulin analogue, Human, Long-acting, 100 u/ml, disposable pen, 3ml   |           | 33 860           |       | Sanofi-Aventis SA (Pty) Ltd           | MAAA0009069                      | V2160                  | OPTISULIN SOLOSTAR 3ML 5                     | R51.06          | 1 x 1                        | 14                             | 5             | 91.00       | 222000179             | EA        |    |
| 68      | Insulin analogue, Human, Ultrafast-acting 100 u/ml, disposable pen, 3ml   |           | 229 559          |       | Sanofi-Aventis SA (Pty) Ltd           | MAAA0009069                      | V2160                  | APIDRA SOLOSTAR 100IU/ML 3 ML 5              | R72.68          | 1 x 1                        | 14                             | 5             | 91.00       | 222000181             | EA        |    |
| 69      | Insulin analogue, Human, Ultrafast-acting 100 u/ml, vial, 10ml  |           | 1 540            |       | Sanofi-Aventis SA (Pty) Ltd           | MAAA0009069                      | V2160                  | APIDRA VIALS 10ML 1                          | R244.95         | 1 x 1                        | 14                             | 10            | 91.00       | 222000182             | VI        |    |
| 70      | Insulin, Biosynthetic, Human, Isophane, 100 u/ml, disposable pen, 3ml   |           | 2 832 200        |       | Novo Nordisk (Pty) Ltd                | MAAA0013414                      | V2743                  | PROTAPHANE HM                                | R32.06          | 1 x 5                        | 14                             | 10            | 92.00       | 180309126             | SG        |    |
| 71      | Insulin, Biosynthetic, Human, Isophane, 100 u/ml, vial, 10ml  |           | 903 640          |       | Novo Nordisk (Pty) Ltd                | MAAA0013414                      | V2743                  | PROTAPHANE HM                                | R34.14          | 1 x 1                        | 14                             | 10            | 92.00       | 189710587             | VI        |    |
| 72      | Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, disposable pen, 3ml   |           | 13 676 740       |       | Novo Nordisk (Pty) Ltd                | MAAA0013414                      | V2743                  | ACTRAPHANE HM                                | R30.37          | 1 x 5                        | 14                             | 10            | 92.00       | 180309129             | SG        |    |
| 74      | Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, vial, 10ml  |           | 4 520 360        |       | Novo Nordisk (Pty) Ltd                | MAAA0013414                      | V2743                  | ACTRAPHANE HM                                | R34.14          | 1 x 1                        | 14                             | 10            | 92.00       | 189711634             | VI        |    |
| 75      | Insulin, Biosynthetic, Human, Soluble, 100 u/ml, disposable pen, 3ml  |           | 1 886 440        |       | Novo Nordisk (Pty) Ltd                | MAAA0013414                      | V2743                  | ACTRAPID HM                                  | R32.06          | 1 x 5                        | 14                             | 10            | 92.00       | 180309128             | SG        |    |



AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH

| Item No | Item Specification  | Estimate  | Quantity Awarded | Split | Supplier Name                         | Central Supplier Database Number | Supplier Code V-Number | Registered Product Name                                | Delivered Price | Pack Size Offered: Unit Pack | Lead-Time (≤ 14 calendar days) | MOQ             | Total Score | National Stock Number | UOM       |    |
|---------|---|-----------|------------------|-------|---------------------------------------|----------------------------------|------------------------|--|-----------------|------------------------------|--------------------------------|-----------------|-------------|-----------------------|-----------|----|
| 76      | Insulin, Biosynthetic, Human, Soluble, 100 u/ml, vial, 10ml   |           | 387 840          |       | Novo Nordisk (Pty) Ltd                | MAAA0013414                      | V2743                  | ACTRAPID HM  | R34.14          | 1 x 1                        | 14                             | 10              | 92.00       | 189710585             | VI        |    |
| 77      | Iron dextran containing elemental iron 50mg/ml, injection, 10ml   |           | 16 500           |       | Litha Pharma (Pty) Ltd (Acino Pharma) | MAAA0009244                      | VGS73                  | COSMOFER   | R310.13         | 1 x 2                        | 14                             | 1 x 2           | 100.00      | 181871852             | AM        |    |
| 78      | Iron dextran containing elemental iron 50mg/ml, injection, 2ml  |           | 211 350          |       | Litha Pharma (Pty) Ltd (Acino Pharma) | MAAA0009244                      | VGS73                  | COSMOFER   | R62.03          | 1 x 5                        | 14                             | 1 x 5           | 100.00      | 181891028             | AM        |    |
| 79      | Iron sucrose containing elemental iron 20mg/ml, injection, 5ml  |           | 271 550          |       | Actor Pharma (Pty) Ltd                | MAAA0183044                      | V2G28                  | Rautevene  | R48.53          | 5 x 5ml ampules              | 14                             | 50              | 90.00       | 180185678             | AM        |    |
| 80      | Insulin analogue, Human, Ultrafast-acting 100 u/ml, penfill cartridge for use in pens, 3ml<br><b>(PENS TO BE PROVIDED FREE OF CHARGE TO PATIENTS)</b> |           | 7 725            |       | Sanofi-Aventis SA (Pty) Ltd           | MAAA0009069                      | V2160                  | APIDRA 300IU CART 5                                    | R69.46          | 1 x 1                        | 14                             | 5               | 91.00       | 222000180             | EA        |    |
| 81      | Ketamine 10mg/ml, injection, 20ml   |           | 96 930           |       | <b>TO FOLLOW</b>                      |                                  |                        |  |                 |                              |                                |                 |             |                       | 189710933 | VI |
| 82      | Ketamine 100mg/ml, injection, 10ml  |           | 61 060           |       | <b>TO FOLLOW</b>                      |                                  |                        |  |                 |                              |                                |                 |             |                       | 189706747 | VI |
| 83      | Ketamine 50mg/ml, injection, 10ml   |           | 87 050           |       | <b>TO FOLLOW</b>                      |                                  |                        |  |                 |                              |                                |                 |             |                       | 189710574 | VI |
| 85      | Lidocaine 1% m/v, injection, not for iv use, 20ml   |           | 1 821 100        |       | B Braun Medical (Pty) Ltd             | MAAA0040832                      | VYL89                  | Lignocaine-HCL B.Braun 1% 20ml (Product Code: 3659091) | R8.38           | 1 x 1                        | 14                             | 20              | 96.00       | 180076306             | VI        |    |
| 86      | Lidocaine 10% m/v, iv injection, 5ml  |           | 39 220           |       | <b>TO FOLLOW</b>                      |                                  |                        |  |                 |                              |                                |                 |             |                       | 180076360 | AM |
| 87      | Lidocaine 2% m/v injection, not for iv use, 20ml  |           | 1 191 930        |       | B Braun Medical (Pty) Ltd             | MAAA0040832                      | VYL89                  | Lignocaine-HCL B.Braun 2% 20ml (Product Code: 3659089) | R8.67           | 1 x 1                        | 14                             | 20              | 96.00       | 189703157             | VI        |    |
| 88      | Lidocaine 2% m/v, Adrenaline 12.5mcg (1:80 000), dental cartridge, 1.8ml  |           | 18 119 370       |       | Adcock Ingram Healthcare (Pty) Ltd    | MAAA0036413                      | V2272                  | Xylotox E80-A  | 6.79            | 100 x 1.8ml box              | 14                             | 1 x 100 x 1.8ml | 100.00      | 180076312             | CA        |    |
| 89      | Lidocaine 2% m/v, dental cartridge, 1.8ml   |           | 2 814 860        |       | Adcock Ingram Healthcare (Pty) Ltd    | MAAA0036413                      | V2272                  | Xylotox S.E. Plain                                     | 6.79            | 100 x 1.8ml box              | 14                             | 1 x 100 x 1.8ml | 99.93       | 180076343             | CA        |    |
| 90      | Lidocaine 2% m/v, iv injection, 5ml   |           | 1 964 420        |       | B Braun Medical (Pty) Ltd             | MAAA0040832                      | VYL89                  | Lignocaine-HCL B. Braun 2% 5ml (Product Code: 3659970) | R2.89           | 1 x 1                        | 14                             | 20              | 96.00       | 180076308             | AM        |    |
| 92      | Magnesium sulfate 50%, injection, 2ml   |           | 5 111 040        |       | Adcock Ingram Critical Care (Pty) Ltd | MAAA0010153                      | V4222                  | SABAX MAGNESIUM SULPHATE 50%                           | R3.45           | 1 x 10 vials                 | 14                             | 10              | 100.00      | 189710942             | AM        |    |
| 93      | Mannitol 25% m/v, injection, 50ml   |           | 19 320           |       | <b>TO FOLLOW</b>                      |                                  |                        |  |                 |                              |                                |                 |             |                       | 189704505 | AM |
| 96      | Methylprednisolone 500mg, (as sodium succinate) injection, 8ml  |           | 100 830          |       | Pfizer Laboratories (Pty) Ltd         | MAAA0019202                      | V2189                  | SOLU-MEDROL 500mg                                      | R159.91         | 1 x 1                        | 14                             | 1               | 91.00       | 189710955             | VI        |    |
| 97      | Methylprednisolone acetate 40mg/ml, injection, 2ml  |           | 257 150          |       | Pfizer Laboratories (Pty) Ltd         | MAAA0019202                      | V2189                  | DEPO-MEDROL 40 mg                                      | R34.88          | 1 x 1                        | 14                             | 1               | 91.00       | 189710776             | VI        |    |
| 98      | Methylprednisolone acetate 40mg/ml, injection, 5ml  |           | 18 412           |       | Pfizer Laboratories (Pty) Ltd         | MAAA0019202                      | V2189                  | DEPO-MEDROL 40 mg                                      | R97.18          | 1 x 1                        | 14                             | 1               | 91.00       | 189710775             | VI        |    |
| 99      | Metoclopramide 5mg/ml, injection, 2ml   | 7 601 990 | 760 199          | 10%   | Pharma-Q (Pty) Ltd                    | MAAA0016762                      | V1NK1                  | Pharma-Q Metoclopramide Inj 10mg/2ml                   | R3.45           | 1 x 10                       | 14                             | 400             | 44.86       | 180076396             | AM        |    |
|         |   |           | 6 841 791        | 90%   | <b>TO FOLLOW</b>                      |                                  |                        |  |                 |                              |                                |                 |             |                       |           |    |
| 100     | Midazolam 1mg/ml, injection, 5ml  | 595 200   | 357 120          | 60%   | Adcock Ingram Critical Care (Pty) Ltd | MAAA0010153                      | V4222                  | ADCO MIDAZOLAM INJECTION 5MG/5ML                       | R6.21           | 1 x 10                       | 14                             | 10              | 92.80       | 180076401             | AM        |    |
|         |   |           | 238 080          | 40%   | Accord Healthcare (Pty) Ltd           | MAAA0005335                      | V2MB8                  | Accord Midazolam 5 mg/5 ml                             | R5.75           | 1 x 10                       | 14                             | 20              | 91.00       |                       |           |    |

AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH

| Item No | Item Specification  | Estimate  | Quantity Awarded | Split | Supplier Name                         | Central Supplier Database Number | Supplier Code V-Number | Registered Product Name                             | Delivered Price | Pack Size Offered: Unit Pack | Lead-Time (≤ 14 calendar days) | MOQ            | Total Score | National Stock Number | UOM       |    |
|---------|---|-----------|------------------|-------|---------------------------------------|----------------------------------|------------------------|---|-----------------|------------------------------|--------------------------------|----------------|-------------|-----------------------|-----------|----|
| 101     | Midazolam 5mg/ml, injection, 10ml   |           | 127 300          |       | Pharma-Q (Pty) Ltd                    | MAAA0016762                      | V1NK1                  | Pharma-Q Midazolam Inj. 50mg/10ml                   | R19.25          | 1 x 10                       | 14                             | 100            | 96.00       | 180018352             | AM        |    |
| 102     | Midazolam 5mg/ml, injection, 3ml  | 948 930   | 569 358          | 60%   | Pharma-Q (Pty) Ltd                    | MAAA0016762                      | V1NK1                  | Pharma-Q Midazolam Inj. 15mg/3ml                    | R7.50           | 1 x 5                        | 14                             | 300            | 96.00       | 180076404             | AM        |    |
| 102     | Midazolam 5mg/ml, injection, 3ml<br><b>Product awarded:</b><br>Midazolam 5mg/ml, injection, 3ml<br>1 pack of 10 injections<br><br><b>Price vs Pack size:</b><br>1 x 1 injection = R8.17<br>1 x 10 injections = R81.70 | 948 930   | 379 572          | 40%   | Adcock Ingram Critical Care (Pty) Ltd | MAAA0010153                      | V4222                  | ADCO MIDAZOLAM INJECTION 15MG/3ML                   | R8.17           | 1 x 10                       | 14                             | 10             | 91.96       | 180076404             | AM        |    |
| 103     | Morphine 10mg/ml, injection, 1ml  | 3 307 110 | 2 976 399        | 90%   | Pharma-Q (Pty) Ltd                    | MAAA0016762                      | V1NK1                  | Pharma-Q Morphine Inj. 10mg/1ml                     | R3.90           | 1 x 10                       | 14                             | 300            | 96.00       | 189703413             | AM        |    |
|         |   |           | 330 711          | 10%   | TO FOLLOW                             |                                  |                        |   |                 |                              |                                |                |             |                       |           |    |
| 104     | Morphine 15mg/ml, injection, 1ml  | 1 772 750 | 1 595 475        | 90%   | Pharma-Q (Pty) Ltd                    | MAAA0016762                      | V1NK1                  | Pharma-Q Morphine Inj. 15mg/1ml                     | R4.10           | 1 x 10                       | 14                             | 300            | 96.00       | 189700425             | AM        |    |
|         |   |           | 177 275          | 10%   | TO FOLLOW                             |                                  |                        |   |                 |                              |                                |                |             |                       |           |    |
| 105     | Naloxone 0.02mg/ml, injection, 2ml  |           | 96 540           |       | TO FOLLOW                             |                                  |                        |   |                 |                              |                                |                |             |                       | 189708068 | AM |
| 106     | Naloxone 0.4mg/ml, injection, 1ml   |           | 504 980          |       | TO FOLLOW                             |                                  |                        |   |                 |                              |                                |                |             |                       | 189705061 | AM |
| 109     | Needle, Insulin, 31G x 5mm, sterile, suitable for use with all prefilled insulin injection devices, 100   |           | 82 770           |       | Unimed Healthcare (Pty) Ltd           | MAAA0444639                      | V92D6                  | INSUPEN 31g X 5mm                                   | R60.02          | 1 x 100                      | 14                             | 36             | 95.61       | 181915212             | BX        |    |
| 110     | Needle, Insulin, 31G x 8mm, sterile, suitable for use with all prefilled insulin injection devices, 100   |           | 377 460          |       | Unimed Healthcare (Pty) Ltd           | MAAA0444639                      | V92D6                  | INSUPEN 31g X 8mm                                   | R56.48          | 1 x 100                      | 14                             | 36             | 99.10       | 181915214             | BX        |    |
| 112     | Neostigmine 2.5mg, injection, 1ml   |           | 481 450          |       | Pharma-Q (Pty) Ltd                    | MAAA0016762                      | V1NK1                  | Pharma-Q Neostigmine Methyl Sulphate Inj. 2.5mg/1ml | R6.16           | 1 x 10                       | 14                             | 200            | 96.00       | 180089506             | AM        |    |
| 113     | Octreotide 0.05mg, injection, 1ml   |           | 14 020           |       | Novartis SA (Pty) Ltd                 | MAAA0006317                      | VBVW2                  | Sandostatin 0.05mg                                  | R 104.36        | 1 x 5                        | 14                             | 1              | 91.00       | 180076442             | AM        |    |
| 114     | Octreotide 0.1mg, injection, 1ml  |           | 119 395          |       | Novartis SA (Pty) Ltd                 | MAAA0006317                      | VBVW2                  | Sandostatin 0.1mg                                   | R 199.10        | 1 x 5                        | 14                             | 1              | 91.00       | 180076445             | AM        |    |
| 116     | Oxytocin 10 iu, injection, 1ml  | 6 406 260 | 3 203 130        | 50%   | Specpharm (Pty) Ltd                   | MAAA0009737                      | V3EQ1                  | Spec Oxytocin 10iu                                  | R15.25          | 1 x 10                       | 14                             | 1 pack of 10's | 99.00       | 180076472             | AM        |    |
| 117     | Oxytocin 5 iu, injection, 1ml   | 2 063 960 | 1 031 980        | 50%   | Specpharm (Pty) Ltd                   | MAAA0009737                      | V3EQ1                  | Spec Oxytocin 5iu                                   | R14.77          | 1 x 10                       | 14                             | 1 pack of 10's | 99.00       | 180076470             | AM        |    |
| 118     | Oxytocin 5iu, Ergometrine 0.5mg, injection, 1ml   |           | 538 290          |       | Adcock Ingram Critical Care (Pty) Ltd | MAAA0010153                      | V4222                  | SYNOMETRINE   | R27.85          | 1 x 5                        | 14                             | 5              | 100.00      | 180076474             | AM        |    |
| 119     | Pantoprazole 40mg, injection, 10ml  |           | 1 042 800        |       | Ranbaxy Pharmaceuticals (Pty) Ltd     | MAAA0000384                      | V4728                  | PANTOCID 40MG INJECTION 10ML                        | R22.94          | 1 x 1                        | 14                             | 10             | 95.00       | 181753528             | VI        |    |
| 120     | Paracetamol 10mg/ml, injection for IV infusion, 100ml   |           | 1 585 240        |       | Biotech Laboratories (Pty) Ltd        | MAAA0029826                      | VUV35                  | PARACETAMOL BIOTECH IV                              | R11.74          | 1 x 100ml                    | 14                             | 10             | 96.00       | 181818827             | VI        |    |
| 122     | Pethidine 25mg/ml, injection, 1ml   |           | 354 260          |       | Pharma-Q (Pty) Ltd                    | MAAA0016762                      | V1NK1                  | Pharma-Q Pethidine Inj. 25mg/1ml                    | R4.60           | 1 x 10                       | 14                             | 400            | 96.00       | 189703124             | AM        |    |
| 123     | Pethidine 50mg/ml, injection, 1ml   | 1 815 320 | 1 452 256        | 80%   | Pharma-Q (Pty) Ltd                    | MAAA0016762                      | V1NK1                  | Pharma-Q Pethidine Inj. 50mg/1ml                    | R4.20           | 1 x 10                       | 14                             | 400            | 96.00       | 180076519             | AM        |    |
|         |   |           | 363 064          | 20%   | TO FOLLOW                             |                                  |                        |   |                 |                              |                                |                |             |                       |           |    |

AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH

| Item No | Item Specification  | Estimate   | Quantity Awarded | Split | Supplier Name                              | Central Supplier Database Number | Supplier Code V-Number | Registered Product Name  | Delivered Price | Pack Size Offered: Unit Pack | Lead-Time (≤ 14 calendar days) | MOQ      | Total Score | National Stock Number | UOM |           |    |
|---------|---|------------|------------------|-------|--|----------------------------------|------------------------|--|-----------------|------------------------------|--------------------------------|----------|-------------|-----------------------|-----|-----------|----|
| 124     | Pethidine 50mg/ml, injection, 2ml   | 2 769 710  | 2 492 739        | 90%   | Pharma-Q (Pty) Ltd                         | MAAA0016762                      | V1NK1                  | Pharma-Q Pethidine Inj. 100mg/2ml                                      | R4.90           | 1 x 10                       | 14                             | 400      | 96.00       | 180076540             | AM  |           |    |
|         |   |            | 276 971          | 10%   | TO FOLLOW                                  |                                  |                        |  |                 |                              |                                |          |             |                       |     |           |    |
| 125     | Phenylephrine 10mg, injection, 1ml<br><br><b>Product awarded:</b><br>Phenylephrine 10mg, injection, 1ml<br>1 pack of 5 injections<br><br><b>Price vs Pack size:</b><br>1 x 1 injection = R67.02<br>1 x 5 injections = R335.10 |            | 637 460          |       | Abbott Laboratories South Africa (Pty) Ltd | MAAA0030395                      | V2150                  | Phenylephrine 10mg, injection, 1ml                                     | R67.02          | 1 x 5                        | 14                             | 1 x 5    | 94.00       | 180076556             | AM  |           |    |
| 126     | Phenytoin 50mg/ml, injection, 5ml   |            | 1 278 200        |       | Ascendis Pharma (Pty) Ltd                  | MAAA0043637                      | V0DM6                  | Phlexy 250 mg/5ml  | R42.48          | 1 x 5ml vial                 | 14                             | 10 vials | 100.00      | 189708084             | VI  |           |    |
| 127     | Phospholipids, Total (Beractant), 100mg/4ml, 1 Vial   |            | 35 215           |       | AbbVie (Pty) Ltd                           | MAAA0076921                      | V3PG3                  | Survanta   | R1 631.44       | 1 x 4ml                      | 14                             | 10       | 91.00       | 181772157             | VI  |           |    |
| 128     | Phospholipids, Total (Beractant), 200mg/8ml, 1 Vial   |            | 17 274           |       | AbbVie (Pty) Ltd                           | MAAA0076921                      | V3PG3                  | Survanta   | R3 262.39       | 1 x 8ml                      | 14                             | 10       | 91.00       | 189753628             | VI  |           |    |
| 129     | Potassium Chloride 15%, m/v injection, 10ml   |            | 2 470 180        |       | TO FOLLOW                                  |                                  |                        |  |                 |                              |                                |          |             |                       |     | 189710612 | AM |
| 130     | Potassium Phosphate Monobasic, Anhydrous, Potassium Phosphate Dibasic Anhydrous, 1.09g/1.05g, injection, 10ml   |            | 131 090          |       | Adcock Ingram Critical Care (Pty) Ltd      | MAAA0010153                      | V4222                  | SABAX POTASSIUM PHOSPHATE SOLUTION FOR INJECTION AFTER DILUTION        | R60.38          | 1 x 10                       | 14                             | 10       | 100.00      | 180076573             | AM  |           |    |
| 131     | Promethazine 25mg/ml, injection, 1ml  |            | 691 430          |       | TO FOLLOW                                  |                                  |                        |  |                 |                              |                                |          |             |                       |     | 189703419 | AM |
| 132     | Promethazine 25mg/ml, injection, 2ml  |            | 319 811          |       | TO FOLLOW                                  |                                  |                        |  |                 |                              |                                |          |             |                       |     | 189703420 | AM |
| 133     | Propofol 10mg/ml, injection, 20ml   |            | 1 446 630        |       | Biotech Laboratories (Pty) Ltd             | MAAA0029826                      | VUV35                  | MILSIA 1 % 20 ml   | R12.69          | 5 x 20ml                     | 14                             | 10       | 96.00       | 180076590             | AM  |           |    |
| 134     | Propofol 10mg/ml, injection, 50ml   |            | 195 590          |       | Biotech Laboratories (Pty) Ltd             | MAAA0029826                      | VUV35                  | MILSIA 1 % 50 ml   | R37.54          | 1 x 50 ml                    | 14                             | 10       | 96.00       | 189763039             | VI  |           |    |
| 136     | Quinine 300mg, injection, 1ml   |            | 46 610           |       | TO FOLLOW                                  |                                  |                        |  |                 |                              |                                |          |             |                       |     | 189706315 | AM |
| 137     | Ranitidine 25mg/ml, injection, 2ml  |            | 822 410          |       | Pharma-Q (Pty) Ltd                         | MAAA0016762                      | V1NK1                  | CPL Alliance Ranitidine Inj. 50mg/2ml                                  | R2.95           | 1 x 10                       | 14                             | 500      | 96.00       | 180076594             | AM  |           |    |
| 138     | Remifentanyl 2mg, injection, 5ml  |            | 47 070           |       | Pharmacare Limited                         | MAAA0008452                      | V2205                  | Fortiva 2 Inj 5x5ml  | R174.80         | 5 x 5ml                      | 14                             | 5        | 95.00       | 181757213             | VI  |           |    |
| 139     | Rocuronium 50mg, injection, 5ml   |            | 777 100          |       | TO FOLLOW                                  |                                  |                        |  |                 |                              |                                |          |             |                       |     | 180960252 | VI |
| 141     | Sodium bicarbonate 4% m/v, injection, 50ml  |            | 109 550          |       | TO FOLLOW                                  |                                  |                        |  |                 |                              |                                |          |             |                       |     | 180358064 | BG |
| 142     | Sodium bicarbonate 8.5% m/v, injection, 50ml  |            | 578 010          |       | TO FOLLOW                                  |                                  |                        |  |                 |                              |                                |          |             |                       |     | 180358068 | BG |
| 143     | Sodium chloride 0.9% m/v, injection, 10ml   | 12 400 540 | 11 160 486       | 90%   | B Braun Medical (Pty) Ltd                  | MAAA0040832                      | VYL89                  | 0.9% Sodium Chloride Injection B. Braun (10ml) (Product Code: 3659990) | R1.48           | 1 x 1                        | 14                             | 100      | 96.00       | 189700088             | AM  |           |    |
|         |   |            | 1 240 054        | 10%   | Adcock Ingram Critical Care (Pty) Ltd      | MAAA0010153                      | V4222                  | SODIUM CHLORIDE 0.9% ADCO  | R2.30           | 1 x 100                      | 14                             | 100      | 50.14       |                       |     |           |    |
| 144     | Somatropin 15iu, powder for injection, cartridge + diluent  |            | 23 720           |       | Novo Nordisk (Pty) Ltd                     | MAAA0013414                      | V2743                  | NORDITROPIN NORDILET 5 MG  | R536.07         | 1 x 1                        | 14                             | 1        | 92.00       | 181808985             | EA  |           |    |

AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH

| Item No | Item Specification  | Estimate | Quantity Awarded | Split | Supplier Name                         | Central Supplier Database Number | Supplier Code V-Number | Registered Product Name                                    | Delivered Price | Pack Size Offered: Unit Pack | Lead-Time (≤ 14 calendar days) | MOQ    | Total Score | National Stock Number | UOM |
|---------|---|----------|------------------|-------|---------------------------------------|----------------------------------|------------------------|--|-----------------|------------------------------|--------------------------------|--------|-------------|-----------------------|-----|
| 145     | Somatropin 30iu, powder for injection, cartridge + diluent  |          | 24 895           |       | Sandoz SA (Pty) Ltd                   | MAAA0011663                      | VVZ69                  | Omnitrope 10mg   | R1 016.00       | 1 x 1                        | 14                             | 100    | 91.00       | 181799365             | EA  |
| 147     | Streptokinase 1.5MU injection   |          | 10 155           |       | Actor Pharma (Pty) Ltd                | MAAA0183044                      | V2G28                  | Fibreaker  | R4 640.80       | 1 x 1                        | 14                             | 5      | 90.00       | 189711674             | VI  |
| 148     | Suxamethonium 50mg/ml, injection, 2ml   |          | 635 010          |       | TO FOLLOW                             |                                  |                        |  |                 |                              |                                |        |             | 180076785             | AM  |
| 152     | Tranexamic Acid 100mg/ml, injection, 5ml<br><b>Product awarded:</b><br>Tranexamic Acid 100mg/ml, injection, 5ml<br>1 pack of 5 injections<br><br><b>Price vs Pack size:</b><br>1 x 1 injection = R37.60<br>1 x 5 injections = R188.00 |          | 1 734 980        |       | Pfizer Laboratories (Pty) Ltd         | MAAA0019202                      | V2189                  | Cyklokapron IV 500   | R37.60          | 1 x 5                        | 14                             | 5      | 91.00       | 180076981             | AM  |
| 153     | Vecuronium 4mg, injection, 2ml  |          | 53 840           |       | Ranbaxy Pharmaceuticals (Pty) Ltd     | MAAA0000384                      | V4728                  | MUSCURON   | R45.94          | 1 x 1                        | 14                             | 5      | 95.00       | 222000188             | EA  |
| 154     | Verapamil HCl 2.5mg/ml, injection, 2ml  |          | 17 910           |       | Pharma-Q (Pty) Ltd                    | MAAA0016762                      | V1NK1                  | Pharma-Q Verapmil Inj. 5mg/2ml                             | R7.20           | 1 x 10                       | 14                             | 100    | 96.00       | 180076998             | AM  |
| 156     | Vitamin B1 (Thiamine) 100mg/ml, injection, 10ml   |          | 412 200          |       | Litha Pharma (Pty) Ltd (Acino Pharma) | MAAA0009244                      | VGS73                  | LITHA THIAMINE INJECTION                                   | R37.56          | 1 x 10                       | 14                             | 1 x 10 | 100.00      | 189700006             | VI  |
| 157     | Vitamin B12 (Cyanocobalamin) 1000mcg, injection, 1ml  |          | 487 350          |       | P & G South African Trading (Pty) Ltd | MAAA0913191                      | VJDY7                  | Neurobion Ampoules   | R48.84          | 3 x 3ml                      | 14                             | 30     | 91.00       | 189715773             | AM  |
| 158     | Vitamin K1 (Phytomenadione) 10mg/1ml, injection   |          | 773 990          |       | Pharmaco Distribution (Pty) Ltd       | MAAA0044115                      | VBVW1                  | KONAKION   | R22.35          | 1 x 10                       | 14                             | 10     | 90.00       | 180146851             | AM  |
| 159     | Vitamin K1 (Phytomenadione) 2mg/0.2ml, injection  |          | 3 500 390        |       | Pharmaco Distribution (Pty) Ltd       | MAAA0044115                      | VBVW1                  | KONAKION   | R13.04          | 1 x 5                        | 14                             | 5      | 90.00       | 180953330             | AM  |
| 160     | Water for injection BP, injection, 10ml   |          | 37 241 680       |       | B Braun Medical (Pty) Ltd             | MAAA0040832                      | VYL89                  | Water for Injections B. Braun 10ml (Product Code: 3659980) | R1.27           | 1 x 1                        | 14                             | 100    | 96.00       | 189710871             | AM  |
| 161     | Water for injection BP, injection, 20ml   |          | 4 112 500        |       | TO FOLLOW                             |                                  |                        |  |                 |                              |                                |        |             | 189710862             | AM  |
| 162     | Zuclopendthixol acetate 50mg, injection, 1ml  |          | 228 680          |       | Lundbeck SA (Pty) Ltd                 | MAAA0031052                      | VVS90                  | Clopixol Acuphase 50 mg/ml                                 | R94.90          | 1 x 1                        | 14                             | 5      | 90.00       | 189753243             | AM  |
| 163     | Zuclopendthixol decanoate 200mg/ml, injection, 1ml  |          | 2 142 750        |       | Lundbeck SA (Pty) Ltd                 | MAAA0031052                      | VVS90                  | Clopixol Depot 200mg/ml                                    | R49.82          | 1 x 1                        | 14                             | 5      | 90.00       | 180057631             | AM  |

| LEGEND UNIT OF MEASUE (UOM) |           |
|-----------------------------|-----------|
| AM                          | Ampoule   |
| BG                          | Bag       |
| BX                          | Box       |
| CA                          | Cartridge |
| EA                          | Each      |
| SG                          | Syringe   |
| VI                          | Vial      |



SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT

---

HP06-2021SVP

SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN  
DEVICES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD  
01 MAY 2021 TO 30 APRIL 2024

BID VALIDITY PERIOD: 120 DAYS

CLOSING DATE AND TIME OF BID:

24 JULY 2020 AT 11H00

*PLEASE NOTE: AN ERRATUM WILL BE PUBLISHED TO AMEND THE CLOSING DATE  
TO 28 SEPTEMBER 2020*

NO BRIEFING SESSION WILL BE HELD.



## TABLE OF CONTENTS

|  |    |
|--|----|
| 1. LEGISLATIVE AND REGULATORY FRAMEWORK .....                        | 7  |
| 10. LATE BIDS.....   | 18 |
| 11. COUNTER CONDITIONS .....   | 19 |
| 12. FRONTING.....  | 19 |
| 13. SUPPLIER DUE DILIGENCE .....                                     | 19 |
| 14. COMMUNICATION .....  | 19 |
| 15. CONTACT DETAILS.....   | 20 |
| 16. CONTRACT PERIOD.....   | 21 |
| 17. PARTICIPATING AUTHORITIES AND OTHER HEALTH ESTABLISHMENT .....   | 21 |
| 18. REGISTRATION ON DATABASES OF PARTICIPATING AUTHORITIES.....      | 21 |
| 19. POST AWARD PARTICIPATION .....                                   | 22 |
| 2. BID INFORMATION SESSION.....                                      | 7  |
| 20. AWARD CONDITIONS.....  | 22 |
| 21. NEGOTIATIONS.....  | 25 |
| 22. NON-COMMITMENT .....   | 25 |
| 23. PRICE REVIEW .....   | 25 |
| 23.1 ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS .....      | 26 |
| 23.2 PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK .....       | 26 |
| 23.3 APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS .....             | 27 |
| 23.4 ROUTINE PRICE ADJUSTMENTS .....                                 | 28 |
| 23.5 EXCEPTIONAL PRICE ADJUSTMENTS.....                              | 28 |
| 23.6 PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW.....             | 29 |
| 24. QUALITY .....  | 29 |
| 25. DELIVERY AND QUANTITIES.....                                     | 30 |
| 26. SUPPLIER PERFORMANCE MANAGEMENT.....                             | 31 |
| 27. PACKAGING, LABELLING AND BARCODES .....                          | 35 |
| 28. SHELF LIFE .....   | 37 |
| 29. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER DETAILS..... | 37 |
| 3. EVALUATION CRITERIA .....   | 7  |
| 3.1 PHASE II: MANDATORY REQUIREMENTS.....                            | 8  |
| 3.1.1 LEGISLATIVE REQUIREMENTS TO THIS BID .....                     | 8  |
| 3.1.2 RESPONSIVE BIDS .....  | 9  |
| 3.1.3 BID RESPONSE DOCUMENT.....                                     | 9  |
| 3.1.4 AUTHORISATION DECLARATION .....                                | 9  |
| 3.1.5 TAX COMPLIANCE STATUS.....                                     | 10 |
| 30. THIRD PARTIES .....  | 38 |
| 4. PHASE III: PRODUCT TECHNICAL COMPLIANCE .....                     | 11 |
| 4.2 COMPLIANCE WITH SPECIFICATIONS .....                             | 13 |
| 5. PHASE IV: PREFERENCE POINT SYSTEM.....                            | 13 |
| 6. PREFERENCE FOR LOCALLY PRODUCED PRODUCTS.....                     | 14 |
| 7. VALUE ADDED TAX.....  | 15 |
| 8. SUBMISSION OF BIDS.....   | 15 |
| 9. COMPLETION OF DOCUMENTS AND BID SUBMISSION.....                   | 17 |
| ABBREVIATIONS .....  | 3  |
| BID DOCUMENT CHECK LIST .....  | 4  |
| SECTION A .....  | 7  |
| SECTION B .....  | 21 |
| SECTION C .....  | 31 |



## ABBREVIATIONS

|        |  |
|--------|--|
| API    | : Active Pharmaceutical Ingredient                   |
| BAC    | : Bid Adjudication Committee                         |
| B-BBEE | : Broad-Based Black Economic Empowerment             |
| CPA    | : Contract Price Adjustment                          |
| CSD    | : Central Supplier Database                          |
| EAN    | : European Article Numbering                         |
| EME    | : Exempted Micro Enterprise                          |
| GMP    | : Good Manufacturing Practice                        |
| MCC    | : Medicines Control Council                          |
| MHPL   | : Master Health Products List                        |
| MPC    | : Master Procurement Catalogue                       |
| NDoH   | : National Department of Health                      |
| PPPFA  | : Preferential Procurement Policy Framework Act      |
| QSE    | : Qualifying Small Enterprise                        |
| RoE    | : Rate of Exchange                                   |
| SAHPRA | : South African Health Products Regulatory Authority |
| SARS   | : South African Revenue Service                      |
| SBD    | : Standard Bidding Document                          |
| VAT    | : Value- Added Tax                                   |

**BID DOCUMENT CHECK LIST**

All bid documents listed below must be sorted, filed and submitted in the **exact** compilation sequence as indicated below and the annexure attached.

Submission of bid documents is compulsory, unless it's not applicable and indicated as such in the "N/A" column.

**All bid documents must be signed.**

Bidders not complying to any of the requirements may be deemed to be non-responsive and will not be considered for evaluation

| Compilation Sequence | Admin Code | Document Name   | N/A | Yes | No | Remark |
|----------------------|------------|---|-----|-----|----|--------|
| 1                    | CL         | Covering Letter   |     |     |    |        |
| 2                    | BSRA       | Bid Signature. Resolution/Authority to sign bid   |     |     |    |        |
| 3                    | BF1        | Bid/File Index  |     |     |    |        |
| 4                    | PBD4.1     | PBD 4.1: Contact Details of Bidder  |     |     |    |        |
| 5                    | SBD5.1     | SBD 1: Invitation to bid  |     |     |    |        |
| 6                    | TCP        | Tax Clearance Pin Issued  |     |     |    |        |
| 7                    | CSD        | CSD Registration report - A certified copy of latest and complete report. <b>Note: CSD summary report will not be accepted.</b> |     |     |    |        |
| 8                    | SBD4       | SBD 4: Declaration of interest  |     |     |    |        |
| 9                    | PBD9       | PBD9: Directors: Categorisation by race, gender and disability  |     |     |    |        |
| 10                   | SBD5       | SBD5: The National Industrial Participation Programme   |     |     |    |        |
| 11                   | SBD6       | SBD 6(1): Preference Points Claimed (B-BBEE)  |     |     |    |        |
| 12                   | BBBEE      | Valid B-BBEE certificate ( <b>certified copy of the original</b> ) or Sworn Affidavit to claim preference points                |     |     |    |        |





| Compilation Sequence | Admin Code | Document Name  | N/A | Yes | No | Remark |
|----------------------|------------|--|-----|-----|----|--------|
| 13                   | SBD8       | SBD 8: Declaration of Past SCM Practices   |     |     |    |        |
| 14                   | SBD9       | SBD 9: Certificate of Independent Bid Determination  |     |     |    |        |
| 15                   | PBD1       | PBD1: Authorisation Declaration<br>Note: Non-compliance to submission of a valid authorisation declaration, where applicable, may invalidate the bid.  |     |     |    |        |
| 16                   | PBD1.1     | PBD 1.1: List of products offered sourced from third party   |     |     |    |        |
| 17                   | PBD1.2     | PBD 1.2: Unconditional written undertaking from the third party.   |     |     |    |        |
| 18                   | PBD5       | PBD5: Good Manufacturing Practice (GMP). Declaration of compliance.  |     |     |    |        |
| 19                   | PBD8       | PBD 8: Special Requirements and Conditions of Contract. Declaration of compliance.   |     |     |    |        |
| 20                   | CIPC       | CIPC/CIPRO or proof of ownership/shareholding. Certified copies of registration certificates   |     |     |    |        |
| 21                   | NC         | Proof of company cedings, mergers and name changes   |     |     |    |        |
| 22                   | LICMI      | Licence to manufacture or import (in the name of the bidder), <b><u>including all annexures. Certified copies required.</u></b>  |     |     |    |        |
| 23                   | LICM       | Licence to manufacture medicines,including all annexures <b><u>for local manufacturing sites</u></b> as listed on the MRC of the bidder (applicant). Certified copies required.  |     |     |    |        |
| 24                   | MRC        | Medicine Registration Certificates (MRC) with all the associated conditions of registration - Certified copies<br><b><u>Note: All MRC's must be marked by the bidder with the relevant item number and be sorted and filed in numerical order.</u></b> |     |     |    |        |



| Compilation Sequence   | Admin Code | Document Name  | N/A | Yes | No | Remark |
|--|------------|--|-----|-----|----|--------|
| 25   | PI         | Original Package Insert (PI) or document detailing professional information approved by the Medicines Control Council (MCC) or the South African Health Products Regulatory Authority (SAHPRA) for each product offered. Note: All PI's must be marked with the relevant item number and be sorted and filed/submitted in numerical order. |     |     |    |        |
| 26   | PS         | Proof of sample submission   |     |     |    |        |
| 27   | BL         | Bidder's item list (List of products offered)  |     |     |    |        |
| 28   | PRICE      | <b>Signed</b> Excel Bid Response Pricing Schedule<br>If the Excel Bid response Pricing Schedule is not signed in the space provided, the bid will not be considered for evaluation.  |     |     |    |        |
| All bid documents listed above must be sorted, filed and submitted in the exact order as indicated above                   |            |  |     |     |    |        |
| Submission of supporting bid documents is compulsory, unless it's not applicable and indicated as such in the "N/A" column |            |  |     |     |    |        |

The bid document check list is available as Annexure A in an excel spreadsheet format and should be completed by all bidders and be submitted in hard copy and as part of the electronic copies of "Set 3: Electronic version of bid documents"



## SECTION A

### 1. LEGISLATIVE AND REGULATORY FRAMEWORK

This bid and all contracts emanating there from will be subject to the Medicines and Related Substances Act, (Act 101 of 1965), Pharmacy Act, (Act 53 of 1974); Patents Act, 1978 (Act 57 of 1978); Trade Marks Act, 1993 (Act 194 of 1993); General Conditions of Contract issued in accordance with Treasury Regulation 16A published in terms of the Public Finance Management Act, 1999 (Act 1 of 1999). The Special Conditions of Contract (SCC) are supplementary to General Conditions of Contract (GCC). Where, however, the Special Conditions of Contract are in conflict with the General Conditions of Contract, the Special Conditions of Contract prevail.

### 2. BID INFORMATION SESSION

As the National Department of Health complies with the regulations made under the Disaster Management Act, 2002, published in the Gazette 18 March 2020 no briefing session or public bid opening will be held.

It is strongly **recommended** that all prospective bidders submit all enquiries to [tenders@health.gov.za](mailto:tenders@health.gov.za) on time to allow the response to reach the bidders before the tender closes.

### 3. EVALUATION CRITERIA

The evaluation process will be conducted in phases as follows:

| Phase I  | Phase II   | Phase III  | Phase IV                 |
|--|--|--|--------------------------|
| Mandatory and other bid requirements                 | Product technical compliance   | Price and B-BBEE                                       | Recommendation and Award |
| Compliance with mandatory and other bid requirements | Compliance with technical specifications<br>Test reports received from sample evaluation | Bids evaluated in terms of the 90/10 preference system | Recommendation and award |



### 3.1 PHASE I: MANDATORY REQUIREMENTS

Bidders must submit all required documents indicated above with the bid documents at the closing date and time of the bid. During this evaluation phase, bidder's responses will be evaluated based on the documents submitted under mandatory requirements. This phase is not scored and bidders who fail to comply with all mandatory requirements will be disqualified.

#### 3.1.1 LEGISLATIVE REQUIREMENTS TO THIS BID

Items offered must be registered in terms of section 15 of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), and must comply with the conditions of registration for the duration of the contract.

**A certified copy** of the original Medicine Registration Certificate, issued in terms of section 15(3) (a) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), must be included with the bid for all items offered.

The bidder must be indicated as the applicant on the Medicines Registration Certificate.

The bidder offering a product must be the holder of a licence to manufacture or import medicines issued in terms of section 22C (1) (b) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) including all annexures. A **certified copy** of the original licence must be submitted by the bidder offering the product.

The bidder offering a product must submit a **certified copy** of the original licence to manufacture medicines, including all annexures for local manufacturing sites listed on the MRC of the bidder who must also be the applicant.

Where an item offered is not eligible for registration in terms of section 15(3) (a) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), a package insert of the item must be supplied.

Bidders must comply with the requirements of the Patents Act, 1978 (Act 57 of 1978) and the Trade Marks Act, 1993 (Act 194 of 1993). Where applicable, an explanation for any non-compliance must be



provided. In the case where a product is manufactured under a voluntary license issued by the patent holder of such a product, a letter authorising the marketing of the product, provided to the bidder by the patent holder must be submitted with the bid.

### 3.1.2 RESPONSIVE BIDS

Bidders are required to submit responsive bids by completing all the prices in the Excel Bid Response. **All prices must be submitted with 2 (two) decimals.** Document and response fields in the fillible PDF bid document. In this regard, bidder's attention is drawn to the document "Definition of fields in the Bid Response Document" explaining the different fields in the bid document.

### 3.1.3 BID DOCUMENTS

Bidders are required to submit responsive bids by completing all the prices, mandatory response fields and item questionnaires.

The excel bid response documents i.e. pricing schedule and Directors: Categorisation of race, gender and disability provided forms an integral part of the bid document and bidders must ensure that it is completed without changing the structure thereof. All pages must be signed.

The prices quoted must be furnished as all inclusive (incl. VAT) on the basis of supply and delivery. **All prices must be submitted with two (2) decimals.**

The bid price offered for a product is deemed to be for the pack size as advertised in the item specification and the unit specified.

Prices submitted must not exceed the ex-manufacturer component of the Single Exit Price inclusive of VAT.

### 3.1.4 AUTHORISATION DECLARATION

Only the holder of a Medicines Registration Certificate issued in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), may submit a bid.



In the event that the Manufacturer, Packer or other entity, as listed on the certificate of registration are external third parties, the bidder must ensure that all legal, financial and supply arrangements have been mutually agreed upon between the bidder and these third parties.

Where a third party is involved in any capacity, the bidder must submit a duly completed and signed Authorisation Declaration (PBD1) for each such third party.

The National Department of Health reserves the right to verify any information supplied by the bidder in the Authorisation Declaration and, should the information be found to be false or incorrect, the National Department of Health will exercise any of the remedies available to it in the bid documents.

Failure to submit a duly completed and signed Authorisation Declaration, with the required annexure(s), in accordance with the above provisions, will invalidate the bid for such goods or services offered.

No agreement between the bidder and any third party will be binding on the National Department of Health.

### 3.1.5 TAX COMPLIANCE STATUS

The Central Supplier Database and the tax compliance status PIN are the approved methods of verifying the tax compliance status of a bidder. The South African Revenue Service does not issue Tax Clearance Certificates anymore but has introduced an online provision via eFiling, for bidders to print their own Tax Clearance Certificates which they can submit with their bids or price quotations.

It is a condition of this bid that the tax matters of the bidder be in order at any point in time, or that satisfactory arrangements have been made with SARS to meet the bidder's tax obligations.

It is a requirement that bidders grant a written confirmation when submitting this bid that SARS may, on an on-going basis during the tenure of the contract, disclose the bidder's tax compliance status and, by submitting this bid, such confirmation is deemed to have been granted.

Bidders are required to be registered on the **Government's Central Supplier Database** and to include in their bid **their Master Registration Number (Supplier Number)** in order to enable the institution to verify the supplier's tax status on the Central Supplier Database;



Foreign suppliers with neither South African tax obligations nor history of doing business in South Africa must complete the questionnaire on the SBD1. Where a recommendation for award of a bid has been made to a foreign bidder, the NDOH will submit the bidder's completed SBD1 to the South African Revenue Service to email address: GovernmentInstitute@sars.gov.za. The South African Revenue Service will issue a confirmation of tax obligations letter to the NDOH, confirming whether or not the foreign entity has tax obligations in South Africa

Should the recommended bidder fail to provide written proof of their tax compliance status, the NDOH will reject the bid submitted by the bidder.

The National Department of Health shall verify the bidder's tax compliance status through the CSD. Where consortia/joint ventures/sub-contractors are involved, each party must be registered on the Central Supplier Database and their tax compliance status will be verified through the Central Supplier Database. Bidders remain responsible to update their CSD information in line with the bid documents submitted for this bid.

#### **4. PHASE II: PRODUCT TECHNICAL COMPLIANCE**

##### **4.1 SAMPLES TO BE SUBMITTED TO HEALTH ESTABLISHMENTS**

All bidders are required to submit samples, including bidders who are currently supplying the National Department of Health with products to confirm the following:

- Compliance with specifications as set out in the bid document/item specification.
- Compliance of the product with the requirements of the Medicines and Related Substances Act, 1965 (Act 101 of 1965).

Failure to submit samples at both health establishments listed below will invalidate the bid for such items offered. Samples are required to be submitted to each (both) of the addresses indicated below prior to closing date and time of bid:



|  |   |
|--|---|
| Mr Dumisani Malele<br>Depot Manager<br>Tel: 011 628 9131<br>Gauteng: Medical Supplies Depot<br>Store 3<br>35 Plunkett Avenue<br>Hurst Hill<br>2092 | Mr Nisaar Mia<br>Pharmaceutical Policy Specialist<br>Tel: 021 483 5800<br>Western Cape: Department of Health<br>4th Floor, Cape Medical Depot<br>16 Chiappini Street<br>Cape Town<br>8001 |
|--|---|

- No samples must be sent to the National Department of Health.
- Samples must be marked with the bid number, the item number as well as the bidder's name and address.
- Bidders must submit at least one original pack of each offer for evaluation.
- It is the responsibility of the bidder to ensure that samples have been received at the addresses provided above.
- All samples for awarded items will be retained for the period of the contract.
- All samples must be a true representation of the product which will be supplied.
- All samples submitted must include the package insert or document detailing professional information approved by the MCC or SAHPRA.
- Proof of sample submission, including a signed copy of the item list as received by the sample evaluation site, must be submitted with the bid documents at the closing date and time of the bid.





## 4.2 COMPLIANCE WITH SPECIFICATIONS

Items must comply with the specification as detailed in the bid document.

## 5. PHASE IV: PREFERENCE POINT SYSTEM

### 5.1 A MAXIMUM OF 80 OR 90 POINTS IS ALLOCATED FOR PRICE ON THE FOLLOWING BASIS:

$$P_s = 80 \left( 1 - \frac{P_t - P_{\min}}{P_{\min}} \right) \quad \text{or} \quad P_s = 90 \left( 1 - \frac{P_t - P_{\min}}{P_{\min}} \right)$$

Where

$P_s$  = Points scored for price of bid under consideration  
 $P_t$  = Price of bid under consideration  
 $P_{\min}$  = Price of lowest acceptable bid

### 5.2 POINTS AWARDED FOR B-BBEE STATUS LEVEL OF CONTRIBUTOR

In terms of Regulation 6(2) and 7(2) of the Preferential Procurement Regulations, preference points must be awarded to a bidder for attaining the B-BBEE status level of contribution in accordance with the table below:

| B-BBEE Status Level of Contributor | Number of points (90/10 system) | Number of points (80/20 system) |
|------------------------------------|---------------------------------|---------------------------------|
| 1                                  | 10                              | 20                              |
| 2                                  | 9                               | 18                              |
| 3                                  | 6                               | 14                              |
| 4                                  | 5                               | 12                              |
| 5                                  | 4                               | 8                               |
| 6                                  | 3                               | 6                               |
| 7                                  | 2                               | 4                               |
| 8                                  | 1                               | 2                               |
| Non-compliant contributor          | 0                               | 0                               |

For this tender, the 90/10 preference point system will be applied.



- Bidders are required to complete the preference claim form (SBD 6.1), and submit a valid certified copy of the original B-BBEE status level verification certificate, at the closing date and time of the bid in order to claim the B-BBEE status level point.
- The points scored by a bidder in respect of the level of B-BBEE contribution will be added to the points scored for price.
- Only bidders who have completed and signed the declaration part of the preference claim form and who have submitted a certified copy of an original B-BBEE status level certificate issued by a registered auditor, accounting officer (as contemplated in section 60(4) of the Close Corporation Act, 1984 (Act No. 69 of 1984)) or an accredited verification agency will be considered for preference points.
- Exempted Micro Enterprises (EME's) and Qualifying Small Enterprises (QSE's) must submit a Sworn Affidavit as prescribed by the B-BBEE Commission, Practice Guide 01 of 2019.
- Sworn Affidavits submitted by EME's and QSE will strictly be evaluated according to the guidelines as prescribed by the B-BBEE Commission.
- If the bidder fails to comply with the paragraphs above, the bidder will be deemed not to have claimed preference points for B-BBEE status level of contribution and will therefore be allocated a zero (0). The National Department of Health may, before a bid is adjudicated or at any time, require a bidder to substantiate claims it has made with regard to preference claimed. The points scored will be rounded off to the nearest two (2) decimals. In the event that two (2) or more bids have scored equal total points, the contract will be awarded to the bidder scoring the highest number of preference points for B-BBEE.
- A contract may, on reasonable and justifiable grounds, be awarded to a bid that did not score the highest number of points.

## 6. PREFERENCE FOR LOCALLY PRODUCED PRODUCTS

The National Department of Health reserves the right to consider locally produced products offered. Bidders are required to indicate on the Excel Bid Response Document where the products are manufactured.

In order to provide preference to locally produced products, the definition of a locally produced product will be limited to product formulation and conversion processes that use materials and components to manufacture medicines (including importation of raw material of active pharmaceutical ingredients (API) and of excipients for production of finished products) in the Republic of South Africa.



Where the National Department of Health gives preference to locally produced products, the quantities for these items will be allocated and awarded proportionately to locally produced products, provided this does not **negatively impact upon security of supply and affordability.**

Bids for products that qualify for this preference must comply with all of the following criteria:

- The South African Health Product Authority (SAHPRA) certificate of registration for a product lists the primary site of production as one that is located in the Republic of South Africa;
- The bidder offering a product must be the holder of a licence to manufacture or import medicines issued in terms of section 22C (1) (b) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) including all annexures. A **certified copy** of the original licence must be submitted by the bidder offering the product.
- The bidder offering a product must submit a **certified copy** of the original licence to manufacture medicines, including all annexures for local manufacturing sites listed on the MRC of the bidder who must also be the applicant.
- The reference price as published by National Department of Health has not been exceeded (if applicable);
- The site/s of manufacture and/or packaging for the product offered is located in South Africa;
- Demonstrated capacity to service the required volumes as evaluated in terms of the data provided in the Excel Bid Response Document;
- Previous supplier performance;
- Compliance to all other aspects contained in these Special Conditions of Contract

## 7. VALUE ADDED TAX

All bid prices must be inclusive of 15% Value-Added Tax. Failure to comply with this condition will invalidate the bid.

## 8. SUBMISSION OF BIDS

All bid documents listed below must be sorted, filed and submitted in the exact compilation sequence as indicated below and the annexure attached.

Submission of bid documents is mandatory, unless it's not applicable and indicated as such in the "N/A" column in the Bid Document Check List.

**All bid documents must be signed.**



Bidders not complying to any of the requirements may be deemed to be non-responsive and will not be considered for evaluation.

- Covering Letter i.e. limited stock availability of any item offered, non-compliance;
- Status relating to TAX, B-BBEE, License to Manufacture, Certificates etc. Bid Signature;
- Resolution/Authority to sign bid;
- Bid/File Index;
- PBD 4.1: Contact Details of Bidder;
- SBD 1: Invitation to bid;
- Tax Clearance Pin Issued;
- CSD Registration report - A certified copy of latest and complete report. Note: CSD summary report will not be accepted;
- SBD 4: Declaration of interest;
- PBD9: Directors: Categorisation by race, gender and disability;
- SBD5: The National Industrial Participation Programme;
- SBD 6(1): Preference Points Claimed (B-BBEE);
- Valid B-BBEE certificate (certified copy) or Sworn Affidavit to claim preference points;
- SBD 8: Declaration of Past SCM Practices;
- SBD 9: Certificate of Independent Bid Determination;
- PBD1: Authorisation Declaration Note: Non-compliance to submission of a valid authorisation declaration, where applicable, may invalidate the bid;
- PBD 1.1: List of products offered sourced from third party;
- PBD 1.2: Unconditional written undertaking from the third party;
- PBD5: Good Manufacturing Practice (GMP). Declaration of compliance;
- PBD 8: Special Requirements and Conditions of Contract. Declaration of compliance;
- CIPC/CIPRO or proof of ownership/shareholding. Certified copies of registration certificates;
- Proof of company cedings, mergers and name changes;
- Certified copy of Licence to manufacture or import (in the name of the bidder), including all annexures;
- Certified copy of Licence to manufacture medicines, including all annexures for local manufacturing sites as listed on the MRC of the bidder (applicant);



- Certified copies of Medicine Registration Certificates (MRC) with all the associated conditions of registration (Annexure). Note: All MRC's must be marked by the bidder with the relevant item number and be sorted and filed in numerical order;
- Original Package Insert (PI) or document detailing professional information approved by the Medicines Control Council (MCC) or the South African Health Products Regulatory Authority (SAHPRA) for each product offered. Note: All PI's must be marked with the relevant item number and be sorted and filed/submitted in numerical order;
- Proof of sample submission;
- Bidder's item list (List of products offered); and
- Signed Excel Bid Response Pricing Schedule (All prices must be submitted in 2 (two) decimals). If the Excel Bid response Pricing Schedule is not signed in the space provided, the bid will not be considered for evaluation

## 9. COMPLETION OF DOCUMENTS AND BID SUBMISSION

Bidders are required to submit three sets of bid documents according to the instructions below. All three sets must be submitted not later than the closing date and time. Set 2 and Set 3 must be included on a CD with Set 1 and submitted in a sealed package. The full name and address of the bidder, including the return address, the bid number and the closing date must be clearly indicated on the package. All fields must be completed. Where information requested is not relevant this should be indicated with N/A.

### **Set 1: Hard copy legally binding bid documents**

Bidders must complete all SBD, PBD and Bid Response forms in black ink, typed. Where no electronic entry field is provided bidders must complete the forms in black ink, handwritten in capital letters. The signed hard copy of the bid document will serve as the legal bid document.

Bidders must submit their complete bid in hard copy format (paper document). The Chief Executive Officer, Chief Financial Officer, or authorised designee of the entity submitting the bid must sign the official signature pages.



All pages in the complete bid document must be initialed by same with black ink. The use of correction fluid is not acceptable. Any change/s must be clearly indicated and initialed.

As the National Department of Health complies with the regulations made under the Disaster Management Act, 2002, published in the Gazette 18 March 2020 no briefing session or public bid opening will be held. However, Bidders must still ensure that bids are delivered on time to the correct address and deposited in the Tender Box. Late bids will not be accepted for consideration

Bidders must refrain from using binding methods like coil, comb, wire velobind, screw binding etc. It is requested that bidders pre-punch two holes on the left hand side of bid documents suitable for filing in a two hole lever arch file. Bid documents should be tied in parcels using string or rope that can be easily untied for filing purposes.

**Set 2: PDF of Hard Copy, signed legal documents. (i.e. pdf of Set 1)**

Bidders must submit a PDF version of the entire signed hardcopy bid, including all certificates and documents requested.

**Set 3: Electronic version of bid documents**

Bidders must submit the electronic versions (editable pdf) of all SBD and PBD documents, Bid Response Document and other relevant spreadsheets in Excel (not pdf).

All three sets of information must be submitted in order for the bid to be evaluated.

Bidders must ensure that the **price quoted** for a product (line item) on the Bid Response Document is for the unit pack as specified. No conversion factors will be applied.

**10. LATE BIDS**

Bids received after the closing date and time, at the address indicated in the bid documents, will not be accepted for consideration and, where practical, be returned unopened to the bidder.



## 11. COUNTER CONDITIONS

Bidders' attention is drawn to the fact that amendments to any of the bid conditions or setting of counter conditions by bidders may result in the invalidation of such bids.

## 12. FRONTING

The National Department of Health supports the spirit of broad based black economic empowerment and recognises that real empowerment can only be achieved through individuals and businesses conducting themselves in accordance with the Constitution and in an honest, fair, equitable, transparent and legally compliant manner. Against this background, the National Department of Health condemns any form of fronting.

The National Department of Health, in ensuring that bidders conduct themselves in an honest manner will, as part of the bid evaluation processes, conduct or initiate the necessary enquiries/investigations to determine the accuracy of the representation made in bid documents. Should any of the fronting indicators as contained in the Guidelines on Complex Structures and Transactions and Fronting, issued by the Department of Trade and Industry, be established during such enquiry/investigation, the onus will be on the bidder/contractor to prove that fronting does not exist. Failure to do so within a period of 14 days from date of notification, may invalidate the bid/ contract and may also result in the restriction of the bidder/contractor to conduct business with the public sector for a period not exceeding 10 years, in addition to any other remedies the National Treasury may have against the bidder/contractor concerned.

## 13. SUPPLIER DUE DILIGENCE

The National Department of Health reserves the right to conduct supplier due diligence prior to final award or at any time during the contract period. This may include site visits to assess whether an item is manufactured at the site specified in the bid and the site complies with quality criteria.

## 14. COMMUNICATION

The National Department of Health, may communicate with bidders where clarity is sought after the closing date and time of the bid and prior to the award of the contract, or to extend the validity period of the bid, if necessary.



Any communication to any government official or a person acting in an advisory capacity for the National Department of Health in respect of this bid between the closing date and the award of the bid by the bidder is discouraged.

All communication between the bidder and the National Department of Health, must be done in writing.

## 15. CONTACT DETAILS

### Postal address

Directorate: Affordable Medicines

Private Bag X828

**PRETORIA**

0001

### Physical address

Directorate: Affordable Medicines

Civitas Building

242 Struben Street

Cnr Thabo Sehume Street

**Pretoria**

0002

Please use the following e-mail address for any queries relating to bidding process:

- [tenders@health.gov.za](mailto:tenders@health.gov.za)





## SECTION B

### 16. CONTRACT PERIOD

The contract shall be for the period from 01 May 2021 to 30 April 2024.

### 17. PARTICIPATING AUTHORITIES AND OTHER HEALTH ESTABLISHMENTS

Participating Authorities and Health Establishments which will be participating authorities in this contract are National Departments, Provincial Departments and other institutions as approved by the accounting officer.

#### Provincial Departments:

- Eastern Cape;
- Free State;
- Gauteng;
- KwaZulu-Natal;
- Limpopo.
- Mpumalanga;
- Northern Cape;
- North West;
- Western Cape; and

#### Other Institutions:

- Nelson Mandela Childrens' Hospital

### 18. REGISTRATION ON DATABASES OF PARTICIPATING AUTHORITIES

All contracted suppliers must register on the supplier databases of Participating Authorities within 30 days after award of contract.

Failure to meet this requirement will result in the inability to process payment for goods.



## 19. POST AWARD PARTICIPATION

Regulation 16A6.6 of the Treasury Regulations for Departments, Trading Entities, Constitutional Entities and Public Entities, issued in terms of the Public Finance Management Act, 1999, (Act 1 of 1999), states that the Accounting Officer/Accounting Authority may, on behalf of a department, constitutional institution or public entity, request to participate in any contract arranged by means of a competitive bidding process by any organ of state, subject to the written approval of such organ of state and the relevant contractors.

## 20. AWARD CONDITIONS

The National Department of Health reserves the right to award contracts to more than one contractor for the same item.

The National Department of Health reserves the right to negotiate prices.

The National Department of Health reserves the right to award the same item as a multiple award to various contractors (two or more) to address high volume requirements, security of supply and product availability.

The following are examples of considerations which may be taken into account when contemplating a multiple award:

- Source of Active Pharmaceutical Ingredient (API) and actual manufacturing site;
- Capacity to meet expected demand as per published estimates in the Excel Bid Response Document;
- Estimated volume to be supplied;
- Risk to public health if the item is not available;
- Past compliance of the bidder with contractual obligations.

In cases where the tender does not achieve the most economically advantageous price, the National Department of Health reserves the right not to award that item. In the case of medicines for chronic conditions, pack sizes suitable for a 28-day treatment cycle are required. Should a 30-day or other pack size be offered, no conversion factor will be applied. Direct comparisons will be made between the 28-day and other pack sizes during evaluation. Similarly, no conversion factors will be applied in cases where a pack size other than that specified is offered.



The National Department of Health may change treatment protocols and/or product formulations where required, due to emerging clinical evidence, disease profiles, safety or resistance patterns and availability of items registered in terms of the Medicines and Related Substances Act, 1965, (Act 101 of 1965) at the date and time of bid closure. In these circumstances, the National Department of Health reserves the right to cancel the contract for an item, or adjust the quantity awarded based on expected changes in projected demand. The Department of Health will notify the contracted supplier within a reasonable time of the expected change. However, in cases where patient safety is a concern, these changes may be implemented with immediate effect.

## 20.1 SPLIT AND MULTIPLE AWARDS

The National Department of Health reserves the right to issue split or multiple awards, where necessary, to ensure security of supply.

The following will be taken into consideration when contemplating a split award:

- Source of API and manufacturing site.
- Capacity to meet expected demand as per published estimates in the Bid Response Document.
- Estimated volume to be supplied.
- Risk to public health if the item is not available.
- Past compliance of the bidder with contractual obligations.

Two-way split awards will be made in accordance with the following schedule based on the points scored:

| Category | Difference between points scored | Recommended percentage split |
|----------|----------------------------------|------------------------------|
| A        | Equal points                     | 50/50                        |
| B        | < 5 points                       | 60/40                        |
| C        | >5-10 points                     | 70/30                        |
| D        | >10-20 points                    | 80/20                        |
| E        | >20 points                       | 90/10                        |



Where a split for more than 2 suppliers is contemplated, the following formula may be used to allocate volumes for award:

- For a three way split: Supplier share = 33.3% + (supplier score - mean score) x 2.3%
- For a four way split: Supplier share = 25% + (supplier score - mean score) x 2%

## 20.2 THERAPEUTIC CLASS AWARDS

The Policy for Classifying Medicines into Therapeutic Classes for Purposes of Therapeutic Interchange defines a therapeutic class as a group of medicines which have active ingredients with comparable therapeutic effects. Medicines in a therapeutic class may or may not belong to the same pharmacological class, may differ in chemistry or pharmacokinetic properties, and may possess different mechanisms of action, result in different adverse reactions, have different toxicity and drug interaction profiles. In most cases, these medicines have close similarity in efficacy and safety profiles, when administered in equipotent doses for a specific indication.

The ministerially appointed National Essential Medicines List Committee (NEMLC) formulates and revises the Standard Treatment Guidelines (STGs) and Essential Medicines List (EML). Therapeutic classes are mentioned in the "Medicine treatment" section of the national STGs which provides a class of medicines followed by an example such as, HMGCoA reductase inhibitors (Statins) e.g. simvastatin. These therapeutic classes have been designated where none of the members of the class offer any significant benefit over member of the class for a specific indication. The NEMLC will designate therapeutic classes for a condition, where appropriate.

Such therapeutic classes may be used during the contracting process to achieve the most economically advantageous contract, offer the market the largest volume and increase the number of competitors, thereby offering the opportunity for cost efficiencies by stimulating robust competition.

**A single member of the class may be awarded.**



| Therapeutic Class and Series Number | Therapeutic class description | Members of the therapeutic class   |
|-------------------------------------|-------------------------------|--|
| Class 1                             | Surfactant - group 1          | Phospholipids, Total (Beractant), 100mg/4ml, 1 Vial<br>Vs<br>Natural Phospholipids (Poractant alpha), intra-tracheal solution, 120mg in 1.5ml, 1.5ml |
| Class 2                             | Surfactant - group 2          | Phospholipids, Total (Beractant), 200mg/8ml, 1 Vial<br>Vs<br>Natural Phospholipids (Poractant alpha), intra-tracheal solution, 240mg in 3ml, 3ml     |

## 21. NEGOTIATIONS

The National Department of Health reserves the right to negotiate with the bidders prior to award and with the successful bidder(s) post award.

## 22. NON-COMMITMENT

The National Department of Health reserves the right not to award, to award in part, or in full.

The right is also reserved to withdraw or amend any of the bid conditions, by notice, in writing to all bidders prior to closing of the bid and post award

In the event that an incorrect award has been made, the National Department of Health reserves the right to remedy the matter in any manner it may deem fit.

## 23. PRICE REVIEW

The National Department of Health envisages three types of price review processes for the duration of this contract:

- A routine adjustment to mitigate foreign exchange fluctuations;
- An exceptional adjustment to mitigate significant short-term foreign exchange fluctuations; and



- A systematic review of prices for comparable products available in the international market place.

## 23.1 ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS

Eligibility for price adjustments relating to foreign exchange risk depends on:

The submission of a complete price breakdown per instructions below for all relevant products; and

Assessment of the rationality of this price breakdown by the National Department of Health.

### 23.1.1 INSTRUCTIONS FOR PRICE BREAKDOWN

- The price breakdown must be completed on the signed bid response document as well as the electronic version. The delivered price must be divided across five components
  - Active Pharmaceutical Ingredients (API);
  - Formulation;
  - Packaging;
  - Logistics (this includes transportation, warehousing and distribution);
  - Gross margin (remaining portion).
- The sum of these categories must be equal to 100% of the delivered price for the line item.
- The local + imported portions of the first three components must add up to 100% within each component (e.g. Portion of API attributable to local + Portion of API attributable to import = 100% of specific API component).
- VAT must be apportioned equally across all components and not regarded as a separate component.
- Labour must be apportioned appropriately across the relevant components.
- Breakdown must be in percentage format to the closest whole percentage (e.g. 20%).
- The National Department of Health reserves the right to engage with bidders to verify any of the components of the bid price, which may include audit of invoices and related documentation.

## 23.2 PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK

Only the portion of the bid price facing foreign exchange risk will be adjusted. This portion is determined by the price breakdown on the signed bid submission.

Adjustments are always calculated using the original awarded contracted price as the base.



Price adjustments relating to foreign exchange will be based on the percentage change between the relevant base average rate of exchange (RoE) and an adjustment average RoE.

Rates are sourced from the Reserve Bank ([www.resbank.co.za](http://www.resbank.co.za)).

Eligibility for favourable Contractual Price Adjustments may be withdrawn in light of evidence of poor compliance with contractual obligations.

Base average RoE for this tender will be as follows, per currency:

| Currency               | Base Average Rates of Exchange Average for the period 1 January 2020 to 30 June 2020 |
|------------------------|--|
| Rand per US Dollar     | 16.61  |
| Rand per Br Pound      | 20.90  |
| Rand per Euro          | 18.30  |
| Rand per Yuan Renminbi | 2.34   |
| Rand per Indian Rupee  | 0.22   |
| Rand per Danish Krone  | 2.43   |

Should the bidder make use of any currency not mentioned above, the bidder must stipulate this clearly and submit the calculated average RoE for the period 1 January 2020 to 30 June 2020 using the South African Reserve Bank published rates for the specific currency.

### 23.3 APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS

Scanned copies of signed applications for price adjustments must be received by the National Department of Health prior to the submission dates detailed in the tables below.

Where no application for an adjustment relating to foreign exchange has been received and such an adjustment would be favourable to the Department, this will be implemented automatically.

Foreign exchange adjustments may never result in a price exceeding the current Single Exit Price, ex Logistics.



#### 23.4 ROUTINE PRICE ADJUSTMENTS

Schedules for routine price reviews, and periods for calculating adjustment average RoE are detailed in the table below:

| <b>Review</b> | <b>Period for calculating adjustment average RoE</b> | <b>Submission of request for price review to reach the office by</b> | <b>Date from which adjusted prices will become effective</b> |
|---------------|--|--|--|
| 1             | 01 May 2021 - 31 October 2021                        | 03 November 2021   | 01 December 2021   |
| 2             | 01 November 2021 - 30 April 2022                     | 03 May 2022  | 01 June 2022   |
| 3             | 01 May 2022 - 31 October 2022                        | 03 November 2022   | 01 December 2022   |
| 4             | 01 November 2022 - 30 April 2023                     | 03 May 2023  | 01 June 2023   |
| 5             | 01 May 2023 - 31 October 2023                        | 03 November 2023   | 01 December 2023   |

#### 23.5 EXCEPTIONAL PRICE ADJUSTMENTS

Suppliers may request exceptional price adjustments according to the schedule in the table below. These will be activated if the absolute change between the base RoE and the three month retrospective average RoE indicated in the table below fluctuates by more than 10%.

| <b>Review</b> | <b>Period for calculating adjustment average RoE</b> | <b>Submission of request for price review to reach the office by</b> | <b>Date from which adjusted prices will become effective</b> |
|---------------|--|--|--|
| 0.1           | 01 May 2021 - 31 July 2021                           | 03 August 2021   | 01 September 2021  |
| 1.1           | 01 November 2021 - 31 January 2022                   | 03 February 2022   | 01 March 2022  |
| 2.1           | 01 May 2022 - 31 July 2022                           | 03 August 2022   | 01 September 2022  |
| 3.1           | 01 November 2022 - 31 January 2023                   | 03 February 2023   | 01 March 2023  |
| 4.1           | 01 May 2023 - 31 July 2023                           | 03 August 2023   | 01 September 2023  |
| 5.1           | 01 November 2023 - 31 January 2024                   | 03 February 2024   | 01 March 2024  |





Suppliers who received exceptional adjustments will receive routine adjustments based on the preceding three months, rather than the usual six month historical average exchange rate. The periods for calculating adjustment average RoE in these instances are detailed in the table below:

| <b>Review</b> | <b>Period for calculating adjustment average RoE</b> | <b>Submission of request for proce review to reach the office by</b> | <b>Date from which adjusted prices will become effective</b> |
|---------------|--|--|--|
| 1             | 01 August 2021 - 31 October 2021                     | 03 November 2021   | 01 December 2021   |
| 2             | 01 February 2022 - 30 April 2022                     | 03 May 2022  | 01 June 2022   |
| 3             | 01 August 2022 - 31 October 2022                     | 03 November 2022   | 01 December 2022   |
| 4             | 01 February 2023 - 30 April 2023                     | 03 May 2023  | 01 June 2023   |
| 5             | 01 August 2023 - 31 October 2023                     | 03 November 2023   | 01 December 2023   |

### 23.6 PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW

The National Department of Health reserves the right to review international prices to identify lowest comparable global prices.

Where this review identifies any prices that are lower than contract prices the National Department of Health will enter into price negotiations with the contracted supplier.

Where the outcome of this negotiation is deemed unfavourable, the National Department of Health reserves the right to terminate the award for the item in question.

### 24. QUALITY

Products must conform to the conditions of registration of the product in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) for the full duration of this contract.



## 25. DELIVERY AND QUANTITIES

### 25.1 DELIVERY BASIS

Firm lead times for delivery must be quoted for the duration of the contract period.

Transit and storage conditions applicable to the relevant products must be adhered to.

The initial lead time as proposed in the bid response document will be calculated from date of award of the contract and NOT the date of placement of the first order. This period may not exceed 75 calendar days from the date of award.

Lead time within the contract period is defined as the time from submission of order to supplier to time of receipt by the Department, as confirmed by the Proof of Delivery document. This lead time may not exceed 14 calendar days.

Failure to comply with the contractual lead time will result in penalties being enforced as per paragraph 21 and 22 of the General Conditions of Contract.

### 25.2 QUANTITIES

The quantities reflected in the bid are estimated quantities and no guarantee is given or implied as to the actual quantity which will be procured during the contract period. Fluctuations in monthly demand may occur.

Proposed minimum order quantities (MOQs) should facilitate delivery directly to health establishments. The National Department of Health reserves the right to negotiate MOQs where necessary. Where consensus regarding MOQs cannot be reached, the bid may not be awarded.

Suppliers are required to maintain sufficient buffer stock to meet at least two-months demand for all items, aligned with the needs of Participating Authorities.



---

## SECTION C

### 26. SUPPLIER PERFORMANCE MANAGEMENT

**26.1 Supplier performance management** will be the responsibility of Participating Authorities with oversight from the National Department of Health and, where supplier performance disputes cannot be resolved between the contractor and the Participating Authority, National Treasury: Transversal Contracting Chief Directorate and National Department of Health must be informed for corrective action.

The National Department of Health, in collaboration with the Participating Authorities, will monitor the performance of contracted suppliers in terms of this contract, including but not limited to the following:

- Compliance with reporting requirements according to reporting schedule and reporting mechanism.
- As a minimum, suppliers will be required to submit the following information in a specified format and via a mechanism defined by the National Department of Health:
  - All transactional data relating to orders;
  - A monthly age analysis;
  - Production pipeline data and forecast including:
    - Number of units of the item available (stock on hand);
    - Number of units of the item in Quality Assurance, awaiting release;
    - Number of units of the item in the current month's production plan.
  - Status of outstanding orders.
- **Attendance of compulsory quarterly meetings**
  - The National Department of Health will hold quarterly meetings with suppliers which will include, but not be limited to, a review of supplier performance and forecasted demand for the next quarter. Suppliers may be required to present continuous improvement initiatives aimed at improving efficiencies in the supply chain to benefit both suppliers and the Department of Health.
- The Participating Authorities shall impose penalties, where deemed necessary, as per Paragraph 21 and 22 of the General Conditions of Contract.
- Non-compliance of contracted suppliers to the terms and conditions of this contract may influence participation in future contracts.



- Contractors should note that each individual purchasing institution is responsible for generating the order(s) as well as for the payment(s) thereof.
- Contractors should note that the order(s) will be placed as and when required during the contract period and delivery points will be specified by the relevant purchasing institution(s).
- The instructions appearing on the official order form regarding the supply, dispatch and submission of invoices must be strictly adhered to and under no circumstances should the contractor deviate from the orders issued by the purchasing institutions.
- The Department of Health is under no obligation to accept any quantity which is in excess of the ordered quantity.
- In order to facilitate efficient implementation of the direct delivery strategy, contracted suppliers must pack orders for the health establishment as per the purchase order.
- Only orders made using an official, authorised purchase order format are valid.
- Suppliers are required to acknowledge receipt of all purchase orders received from Participating Authorities, in a manner stipulated by the relevant Participating Authority.
- Changes to any quantities ordered may only be made upon receipt of an amended purchase order.
- The Participating Authorities reserve the right to cancel orders where the lead time exceeds the delivery lead time specified in the contract and may, at their discretion, purchase supplies of a similar quality and up to the same quantity in substitution of the goods not supplied in conformity with the contract (as per paragraph 21.6 of the General Conditions of Contract).
- In cases where an order is received which appears to be irrational or misaligned with estimates, the contracted supplier must liaise with the relevant Participating Authority prior to processing the order.

## 26.2 DELIVERY ADHERENCE

- Products and related documentation must be delivered in accordance with the terms, conditions and delivery instructions stipulated on the purchase order.
- The information on invoices and documents relating to delivery must comply with the minimum data requirements as defined by the National Department of Health.
- Invoices must reflect both the "proprietary name "(brand name"/"trade name") which is unique to a particular medicine, and which is the name approved in terms of section 15(4) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), and the item description as it appears in the contract



circular and Master Procurement Catalogue (MPC), or Master Health Product List (MHPL), which will replace the MPC.

- Original invoices and proof of delivery must be authorised by a delegated official at the designated delivery point. These documents must be delivered to the authority responsible for payment. This may or may not be the same as the delivery address stipulated on the purchase order. Suppliers are required to know where documents must be delivered.
- The supplier must ensure that products are delivered in accordance with the appropriate conditions of storage, as per product's conditions of registration. Delivery is deemed to terminate upon signature of receipt by the delegated official.
- Discrepancies between invoice and physical stock, or damaged stock, will be reported to the contracted supplier within a reasonable time or as arranged with the supplier. This time period must make provision for the quantities received to be checked upon receipt of delivery.
- Contracted suppliers will be responsible for collection of goods delivered erroneously, or in the incorrect condition as formally arranged in consultation with the purchasing authority. The Participating Authorities may recoup any expenses associated with failure to collect such goods in accordance with the agreement

### 26.3 CONTINUITY OF SUPPLY

- Contracted suppliers must have at least two months' supply of the estimate at the start of the contract.
- Contractors must maintain sufficient buffer stock throughout the duration of the contract.
- Contractors must inform National Department of Health at first knowledge of any circumstances that may result in interrupted supply, including but not limited to:
  - regulatory action which may impact on their GMP status or that of entities on which they are reliant;
  - any anticipated problems associated with the availability of active pharmaceutical ingredient (API);
  - industrial action
  - challenges with manufacturing pipeline;
  - any other supply challenges.
- Contractors must direct official communication relating to continuity of supply to [stockalert@health.gov.za](mailto:stockalert@health.gov.za), as well as Participating Authorities.
- Contractors must direct official communication relating to payment challenges to [medacc@health.gov.za](mailto:medacc@health.gov.za), as well as Participating Authorities.



- All official communication must include detail of corrective actions taken by the contracted supplier to ensure continuity of supply.
- It is the responsibility of the contracted supplier to ensure continuous availability and supply of contracted items. In the event that the contracted supplier is unable to supply, the contracted supplier is required to source alternative product of acceptable quality and up to the same quantity as required for a period of not more than three months. In the case of a multiple award, the alternative product should not be sourced from another contracted supplier for the same product.
- In the event that a contracted supplier is unable to supply in the short term, the National Department of Health reserves the right to proportionally reallocate volumes to an alternative contracted supplier for the duration of the contracted supplier's inability to supply.
- Prior to the supply of an alternative product can be undertaken, the contracted supplier is required to submit the samples of the product to be supplied to the two health establishments as listed in section 4. The contracted supplier is also required to furnish the Department of Health with the following information:
  - Name of the product to be supplied;
  - The quantities to be supplied; and
  - The period for which the product will be supplied.
  - The alternative product must be supplied at the current price of the contracted item.
  - This provision is only applicable for emergency supply and cannot be used for routine and continuous supply of the product.
  - Suppliers may be required to pay penalties for supply exceeding the contractual lead time as stipulated in the General Conditions of Contract Paragraph 22.
  - In terms of the General Conditions of Contract and Special Requirements and Conditions of Contract, the Participating Authorities may purchase outside the contract in order to meet its requirements if the item is urgently required and is not immediately available.

#### 26.4 REPORTING

National Department of Health will provide the requirements for reporting and successful bidders will be assisted with complying with these requirements.

The National Department of Health may, from time to time and within reason, add to the reporting requirements. Any changes to reporting requirements or the reporting mechanism will be communicated in writing by the Directorate: Affordable Medicines.



## 27. PACKAGING, LABELLING AND BARCODES

### 27.1 PACKAGING

- Suppliers must ensure that products delivered are received in good order at the point of delivery. Packaging must be suitable for further dispatch, storage and stacking according to Good Wholesaling Practice and Good Distribution Practice.
- Packaging must be suitable for transportation and should prevent exposure to conditions that could adversely affect the stability and integrity of the product.
- The packaging must be uniform for the duration of the contract period. All products must be packaged in acceptable containers, specifically developed for the product.
- The number of units per shipper pack or original carton must be completed in the Bid Response Document.
- Where a particular stacking and storage configuration is recommended by the supplier, this should be clearly illustrated on the outer packaging.
- Where the contents of the shipper pack represent a standard supply quantity of an item, the following must be adhered to:
  - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering;.
  - The contents must be packed in neat, uniform rows and columns that will facilitate easy counting when opened.
  - Where the contents of a shipper pack represent a non-standard supply quantity, the following must be adhered to:
    - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering;.
    - The shipper pack must contain only one product, mixing of multiple products in a single shipper is not allowed;.
    - The outer packaging must be clearly marked as a "Part Box".



## 27.2 LABELLING

- All containers, packaging and cartons must be clearly labelled. Bulk packs must be labelled in letters not less than font size 48.
- The following information must be clearly and indelibly printed on all shipper packs, including any part boxes:
  - Item name as contained in the contract circular and the Master Procurement Catalogue (MPC), or Master Health Products List (MHPL), which will replace the MPC.
  - Registered product name (if applicable);
  - Number of units in pack
  - Batch number;
  - Expiry date;
  - Storage conditions;
  - Barcode.
- Where the contents of the shipper pack require special attention in terms of storage and/or handling, e.g. thermolabile, high-scheduled or cytotoxic products, such instructions must be clearly and visibly indicated on the outer packaging on a brightly coloured background.
- Unit packs must be labelled in accordance with Regulation 10 of the General Regulations published in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965). The label must include a barcode suitable for the identification and tracking of medication.

## 27.3 BARCODES

- All unit and shipper packs must be marked with the appropriate barcode number and symbology.
- The European Article Numbering Code 13 (EAN 13) has been accepted as standard.
- Suppliers are encouraged to include a 2D barcode or similar on their packaging that will include the following information:
  - Item name as contained in the contract circular and the Master Procurement Catalogue (MPC), or Master Health Products List (MHPL) which will replace the MPC.
  - The "proprietary name (brand name"/"trade name") unique to a particular medicine, as approved by MCC or SAHPRA;
    - Dosage form and strength;
    - Pack size;





- Batch number;
- Expiry date.

## 28 SHELF LIFE

- Unless MCC or SAHPRA, has approved a shorter shelf life, products must have a shelf-life of at least 12 months upon delivery.
- Contracted suppliers may apply in writing to Participating Authorities to supply a product with a shorter shelf life provided that:
  - Applications are accompanied by an undertaking that such short-dated products will be unconditionally replaced or credited before or after expiry; and
  - Applications are approved by the Participating Authorities before execution of orders; and
  - Upon notification of remaining expired stock such products will be collected by the supplier at their own cost; and
  - Failure to collect the products within 30 days after written notification to the supplier will result in the disposal of the product by the Participating Authority for the account of the supplier.
- If short-dated products are delivered without the aforementioned undertaking the following discount formula will be applied for invoicing of short-dated products:
  - $A = (12 - \text{months to date of expiry}) \times 2\% \times \text{consignment value short dated product}$ . Therefore, amount to be invoiced is: Consignment value minus A, where A is the value of the outcome of the discount formula.
- Unless otherwise agreed to, any Participating Authority may, without prejudice, decline to accept product with a shelf-life of less than 12 months.

## 29. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER DETAILS

Where a contracted supplier plans to merge with, or is going to be acquired by, another entity or plans to cede a contract the contracted supplier must inform the National Department of Health in writing at first knowledge of such an event.

Where a contracted supplier plans to cede a contracted item to another supplier, the contracted supplier must submit an official request in writing to the NDOH, three months prior to the proposed effective date.



The NDOH reserves the right to accept or decline the request to cede the contractual obligations to the new supplier under the prevailing conditions of contract or to cancel the contract.

The contracted supplier is obliged to supply the contracted item under the prevailing conditions of contract, until such time that the NDOH has approved the request to cede the item to another supplier.

The contracted supplier must inform the National Department of Health at first knowledge of any changes to address, name, or contact details and effect these changes on the Central Supplier Database.

### **30. CANCELLATION OF THE CONTRACT**

Cancellation of a contract will only be considered after compelling evidence to support the request has been submitted to the satisfaction of the Department of Health.

The contracted supplier is obliged to supply the contracted item under the prevailing conditions of contract, until such time that the NDOH has approved the request to cancel the item.

### **31. THIRD PARTIES**

Participating Authorities will not make a payment to or consult with a third party.

No third party is entitled to put an account of a Participating Authority on hold.

END

| Item No | Description   | Therapeutic Class Numbers | Unit | Estimate  |
|---------|---|---------------------------|------|-----------|
| 1       | Acetylcysteine 200mg/ml, injection, 10ml                      |                           | Each | 213,295   |
| 2       | Adenosine 3mg/ml, injection, 2ml                              |                           | Each | 74,740    |
| 3       | Adrenaline (Epinephrine) 0.15mg/0.3ml, auto-injection, 0.3ml  |                           | Each | 5,570     |
| 4       | Adrenaline (Epinephrine) 0.3mg/0.3ml, auto-injection, 0.3ml   |                           | Each | 2,336     |
| 5       | Adrenaline (Epinephrine) 1mg/ml, injection, 1ml               |                           | Each | 7,520,710 |
| 6       | Alfentanil 0.5mg/ml, injection, 2ml                           |                           | Each | 119,310   |
| 7       | Alprostadil 0.5mg/ml, injection, 1ml                          |                           | Each | 6,250     |
| 8       | Alteplase 50mg, 1 Vial  |                           | Each | 7,960     |
| 9       | Aminophylline 25mg/ml, injection, 10ml                        |                           | Each | 354,560   |
| 10      | Amiodarone 50mg/ml, injection, 3ml                            |                           | Each | 223,660   |
| 11      | Atracurium 10mg/ml, injection, 2.5ml                          |                           | Each | 81,270    |
| 12      | Atracurium 10mg/ml, injection, 5ml                            |                           | Each | 58,400    |
| 13      | Atropine 0.5mg/ml, injection, 1ml                             |                           | Each | 1,278,840 |
| 14      | Atropine 1mg injection, 1ml                                   |                           | Each | 2,353,110 |
| 15      | Betamethasone 4mg/ml, injection, 1ml                          |                           | Each | 1,199,860 |
| 16      | Biperiden 5mg, injection, 1ml                                 |                           | Each | 63,180    |
| 17      | Bupivacaine 5mg, Adrenaline 5mcg/ml, injection, 20ml          |                           | Each | 292,780   |
| 18      | Bupivacaine 5mg, Dextrose Anhydrous 72.7mg/ml, injection, 4ml |                           | Each | 974,370   |
| 19      | Bupivacaine 5mg/ml injection, spinal, 4ml                     |                           | Each | 206,140   |
| 20      | Bupivacaine 5mg/ml, injection, 10ml                           |                           | Each | 971,660   |
| 21      | Caffeine 20mg/ml, injection, 1ml                              |                           | Each | 185,250   |
| 22      | Calcium gluconate 10% m/v, injection, 10ml                    |                           | Each | 754,340   |
| 23      | Cisatracurium 2mg/ml, injection, 2.5 ml                       |                           | Each | 266,650   |
| 24      | Cisatracurium 2mg/ml, injection, 5ml                          |                           | Each | 237,390   |
| 25      | Clonazepam 1mg/ml, injection, 1ml                             |                           | Each | 514,285   |
| 26      | Clotiapine 10mg/ml, injection, 4ml                            |                           | Each | 78,395    |
| 27      | Dantrolene 20mg, injection, 70 ml                             |                           | Each | 2,280     |
| 28      | Desferrioxamine 500mg, injection                              |                           | Each | 49,970    |
| 29      | Desmopressin 4mcg, injection, 1ml                             |                           | Each | 9,660     |
| 30      | Dexamethasone 4mg, injection, 1ml                             |                           | Each | 5,270,300 |
| 31      | Dexmedetomidine, 100 mcg/ml, Injection for infusion, 2ml      |                           | Each | 58,320    |
| 32      | Dextrose 50% m/v, injection, 20ml                             |                           | Each | 1,293,980 |
| 33      | Dextrose 50% m/v, injection, 50ml                             |                           | Each | 1,140,740 |
| 34      | Diazepam 5mg/ml, injection, 2ml                               |                           | Each | 771,330   |
| 35      | Diclofenac 25mg/ml, injection, 3ml                            |                           | Each | 8,327,390 |
| 36      | Digoxin 0,25mg/ml, injection, 2ml                             |                           | Each | 39,280    |
| 37      | Dinoprost 5mg, injection, 1ml                                 |                           | Each | 900       |
| 38      | Dobutamine 12.5mg/ml, injection, 20ml                         |                           | Each | 206,440   |
| 39      | Dopamine 40mg/ml, injection, 5ml                              |                           | Each | 106,755   |
| 40      | Enoxaparin 40mg, injection, 0.4ml                             |                           | Each | 8,663,680 |
| 41      | Enoxaparin 60mg, injection, 0.6ml                             |                           | Each | 901,800   |
| 42      | Enoxaparin 80mg, injection, 0.8ml                             |                           | Each | 2,019,230 |
| 43      | Ephedrine 50mg, injection, 1ml                                |                           | Each | 325,270   |
| 44      | Ergometrine 0.5mg, injection, 1ml                             |                           | Each | 24,700    |
| 45      | Erythropoietin 10 000 iu, injection, 0.6ml                    |                           | Each | 88,800    |
| 46      | Erythropoietin 2 000 iu, injection, 0.3ml                     |                           | Each | 320,510   |
| 47      | Erythropoietin 30 000 iu, injection, 0.6ml                    |                           | Each | 6,520     |
| 48      | Erythropoietin 4 000 iu, injection, 0.3ml                     |                           | Each | 683,630   |

| Item No | Description  | Therapeutic Class Numbers | Unit | Estimate   |
|---------|--|---------------------------|------|------------|
| 49      | Erythropoietin 6 000 iu, injection, 0.3ml  |                           | Each | 13,624     |
| 50      | Etomidate 2mg/ml, injection, 10ml  |                           | Each | 145,080    |
| 51      | Fentanyl 0.05mg/ml, injection, 2ml   |                           | Each | 1,581,570  |
| 52      | Fentanyl 0.05mg/ml, injection, 10ml  |                           | Each | 370,850    |
| 53      | Fluorescein 100mg/ml, injection, 5ml   |                           | Each | 1,536      |
| 54      | Flupenthixol decanoate 20mg/ml, injection, 1ml   |                           | Each | 1,507,530  |
| 55      | Furosemide 10mg/ml, injection, 25ml  |                           | Each | 245,280    |
| 56      | Furosemide 10mg/ml, injection, 2ml   |                           | Each | 7,085,900  |
| 57      | Furosemide 10mg/ml, injection, 5ml   |                           | Each | 342,230    |
| 58      | Glucagon 1mg, injection, 1ml   |                           | Each | 30,050     |
| 59      | Glyceryl trinitrate 1mg/ml, injection, 10ml  |                           | Each | 146,900    |
| 60      | Glycopyrronium bromide 0.2mg/ml, injection, 2ml  |                           | Each | 622,200    |
| 61      | Haloperidol 10mg/ml, injection, 2ml  |                           | Each | 24,220     |
| 62      | Haloperidol 5mg/ml, injection, 1ml   |                           | Each | 447,790    |
| 63      | Heparin 1000 iu/ml, injection, 5ml   |                           | Each | 693,310    |
| 64      | Heparin 5000 iu/ml, injection, 5ml   |                           | Each | 946,240    |
| 65      | Hydrocortisone 100mg/2ml, injection, 2ml   |                           | Each | 4,166,740  |
| 66      | Hyoscine Butylbromide 20mg, injection, 1ml   |                           | Each | 2,338,110  |
| 67      | Insulin analogue, Human, Long-acting, 100 u/ml, disposable pen, 3ml  |                           | Each | 33,860     |
| 68      | Insulin analogue, Human, Ultrafast-acting 100 u/ml, disposable pen, 3ml  |                           | Each | 229,559    |
| 69      | Insulin analogue, Human, Ultrafast-acting 100 u/ml, vial, 10ml   |                           | Each | 1,540      |
| 70      | Insulin, Biosynthetic, Human, Isophane, 100 u/ml, disposable pen, 3ml  |                           | Each | 2,832,200  |
| 71      | Insulin, Biosynthetic, Human, Isophane, 100 u/ml, vial, 10ml   |                           | Each | 903,640    |
| 72      | Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, disposable pen, 3ml  |                           | Each | 11,488,740 |
| 73      | Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, penfill cartridge for use in pens, 3ml<br>(PENS TO BE PROVIDED FREE OF CHARGE TO PATIENTS) |                           | Each | 2,188,000  |
| 74      | Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, vial, 10ml   |                           | Each | 4,520,360  |
| 75      | Insulin, Biosynthetic, Human, Soluble, 100 u/ml, disposable pen, 3ml   |                           | Each | 1,886,440  |
| 76      | Insulin, Biosynthetic, Human, Soluble, 100 u/ml, vial, 10ml  |                           | Each | 387,840    |
| 77      | Iron dextran containing elemental iron 50mg/ml, injection, 10ml  |                           | Each | 16,500     |
| 78      | Iron dextran containing elemental iron 50mg/ml, injection, 2ml   |                           | Each | 211,350    |
| 79      | Iron sucrose containing elemental iron 20mg/ml, injection, 5ml   |                           | Each | 271,550    |
| 80      | Insulin analogue, Human, Ultrafast-acting 100 u/ml, penfill cartridge for use in pens, 3ml<br>(PENS TO BE PROVIDED FREE OF CHARGE TO PATIENTS)                             |                           | Each | 7,725      |
| 81      | Ketamine 10mg/ml, injection, 20ml  |                           | Each | 96,930     |
| 82      | Ketamine 100mg/ml, injection, 10ml   |                           | Each | 61,060     |
| 83      | Ketamine 50mg/ml, injection, 10ml  |                           | Each | 87,050     |
| 84      | Labetalol 5mg/ml, injection, 20ml  |                           | Each | 193,390    |
| 85      | Lidocaine 1% m/v, injection, not for iv use, 20ml  |                           | Each | 1,821,100  |
| 86      | Lidocaine 10% m/v, iv injection, 5ml   |                           | Each | 39,220     |
| 87      | Lidocaine 2% m/v injection, not for iv use, 20ml   |                           | Each | 1,191,930  |
| 88      | Lidocaine 2% m/v, Adrenaline 12.5mcg (1:80 000), dental cartridge, 1.8ml   |                           | Each | 18,119,370 |
| 89      | Lidocaine 2% m/v, dental cartridge, 1.8ml  |                           | Each | 2,814,860  |
| 90      | Lidocaine 2% m/v, iv injection, 5ml  |                           | Each | 1,964,420  |
| 91      | Lorazepam 4mg, injection, 1ml  |                           | Each | 977,050    |
| 92      | Magnesium sulfate 50%, injection, 2ml  |                           | Each | 5,111,040  |
| 93      | Mannitol 25% m/v, injection, 50ml  |                           | Each | 19,320     |
| 94      | Methylprednisolone 125mg, (as sodium succinate) injection, 2ml   |                           | Each | 33,765     |

| Item No | Description   | Therapeutic Class Numbers | Unit | Estimate  |
|---------|---|---------------------------|------|-----------|
| 95      | Methylprednisolone 40mg, (as sodium succinate) injection, 1ml   |                           | Each | 5,160     |
| 96      | Methylprednisolone 500mg, (as sodium succinate) injection, 8ml  |                           | Each | 100,830   |
| 97      | Methylprednisolone acetate 40mg/ml, injection, 2ml  |                           | Each | 257,150   |
| 98      | Methylprednisolone acetate 40mg/ml, injection, 5ml  |                           | Each | 18,412    |
| 99      | Metoclopramide 5mg/ml, injection, 2ml   |                           | Each | 7,601,990 |
| 100     | Midazolam 1mg/ml, injection, 5ml  |                           | Each | 595,200   |
| 101     | Midazolam 5mg/ml, injection, 10ml   |                           | Each | 127,300   |
| 102     | Midazolam 5mg/ml, injection, 3ml  |                           | Each | 948,930   |
| 103     | Morphine 10mg/ml, injection, 1ml  |                           | Each | 3,307,110 |
| 104     | Morphine 15mg/ml, injection, 1ml  |                           | Each | 1,772,750 |
| 105     | Naloxone 0.02mg/ml, injection, 2ml  |                           | Each | 96,540    |
| 106     | Naloxone 0.4mg/ml, injection, 1ml   |                           | Each | 504,980   |
| 107     | Natural Phospholipids (Poractant alpha), intra-tracheal solution, 120mg in 1.5ml, 1.5ml                       | Class 1                   | Each | 35,215    |
| 108     | Natural Phospholipids (Poractant alpha), intra-tracheal solution, 240mg in 3ml, 3ml                           | Class 2                   | Each | 17,274    |
| 109     | Needle, Insulin, 31G x 5mm, sterile, suitable for use with all prefilled insulin injection devices, 100       |                           | Each | 82,770    |
| 110     | Needle, Insulin, 31G x 8mm, sterile, suitable for use with all prefilled insulin injection devices, 100       |                           | Each | 377,460   |
| 111     | Neostigmine 0.5mg, injection, 1ml   |                           | Each | 107,590   |
| 112     | Neostigmine 2.5mg, injection, 1ml   |                           | Each | 481,450   |
| 113     | Octreotide 0.05mg, injection, 1ml   |                           | Each | 14,020    |
| 114     | Octreotide 0.1mg, injection, 1ml  |                           | Each | 119,395   |
| 115     | Octreotide 0.2mg/ml, injection, 5ml   |                           | Each | 8,380     |
| 116     | Oxytocin 10 iu, injection, 1ml  |                           | Each | 6,406,260 |
| 117     | Oxytocin 5 iu, injection, 1ml   |                           | Each | 2,063,960 |
| 118     | Oxytocin 5iu, Ergometrine 0.5mg, injection, 1ml   |                           | Each | 538,290   |
| 119     | Pantoprazole 40mg, injection, 10ml  |                           | Each | 1,042,800 |
| 120     | Paracetamol 10mg/ml, injection for IV infusion, 100ml   |                           | Each | 1,585,240 |
| 121     | Paracetamol 10mg/ml, injection for IV infusion, 50ml  |                           | Each | 6,910     |
| 122     | Pethidine 25mg/ml, injection, 1ml   |                           | Each | 354,260   |
| 123     | Pethidine 50mg/ml, injection, 1ml   |                           | Each | 1,815,320 |
| 124     | Pethidine 50mg/ml, injection, 2ml   |                           | Each | 2,769,710 |
| 125     | Phenylephrine 10mg, injection, 1ml  |                           | Each | 637,460   |
| 126     | Phenytoin 50mg/ml, injection, 5ml   |                           | Each | 1,278,200 |
| 127     | Phospholipids, Total (Beractant), 100mg/4ml, 1 Vial   | Class 1                   | Each | 35,215    |
| 128     | Phospholipids, Total (Beractant), 200mg/8ml, 1 Vial   | Class 2                   | Each | 17,274    |
| 129     | Potassium Chloride 15%, m/v injection, 10ml   |                           | Each | 2,470,180 |
| 130     | Potassium Phosphate Monobasic, Anhydrous, Potassium Phosphate Dibasic Anhydrous, 1.09g/1.05g, injection, 10ml |                           | Each | 131,090   |
| 131     | Promethazine 25mg/ml, injection, 1ml  |                           | Each | 691,430   |
| 132     | Promethazine 25mg/ml, injection, 2ml  |                           | Each | 319,811   |
| 133     | Propofol 10mg/ml, injection, 20ml   |                           | Each | 1,446,630 |
| 134     | Propofol 10mg/ml, injection, 50ml   |                           | Each | 195,590   |
| 135     | Protamine 10mg/ml, injection, 5ml   |                           | Each | 52,140    |
| 136     | Quinine 300mg, injection, 1ml   |                           | Each | 46,610    |
| 137     | Ranitidine 25mg/ml, injection, 2ml  |                           | Each | 822,410   |
| 138     | Remifentanyl 2mg, injection, 5ml  |                           | Each | 47,070    |
| 139     | Rocuronium 50mg, injection, 5ml   |                           | Each | 777,100   |
| 140     | Salbutamol 0.5mg, injection, 1ml  |                           | Each | 301,240   |
| 141     | Sodium bicarbonate 4% m/v, injection, 50ml  |                           | Each | 109,550   |

| Item No | Description  | Therapeutic Class Numbers | Unit | Estimate   |
|---------|--|---------------------------|------|------------|
| 142     | Sodium bicarbonate 8.5% m/v, injection, 50ml               |                           | Each | 578,010    |
| 143     | Sodium chloride 0.9% m/v, injection, 10ml                  |                           | Each | 12,400,540 |
| 144     | Somatropin 15iu, powder for injection, cartridge + diluent |                           | Each | 23,720     |
| 145     | Somatropin 30iu, powder for injection, cartridge + diluent |                           | Each | 24,895     |
| 146     | Somatropin 36iu, powder for injection, cartridge + diluent |                           | Each | 426        |
| 147     | Streptokinase 1.5MU injection                              |                           | Each | 10,155     |
| 148     | Suxamethonium 50mg/ml, injection, 2ml                      |                           | Each | 635,010    |
| 149     | Testosterone 1g injection, 1 injection                     |                           | Each | 16,415     |
| 150     | Thiopentone 0.5g, injection, 20ml                          |                           | Each | 23,540     |
| 151     | Tramadol 50mg/ml, injection, 2ml                           |                           | Each | 3,207,480  |
| 152     | Tranexamic Acid 100mg/ml, injection, 5ml                   |                           | Each | 1,734,980  |
| 153     | Vecuronium 4mg, injection, 2ml                             |                           | Each | 53,840     |
| 154     | Verapamil HCl 2.5mg/ml, injection, 2ml                     |                           | Each | 17,910     |
| 155     | Vitamin B Complex, injection, 10ml                         |                           | Each | 429,600    |
| 156     | Vitamin B1 (Thiamine) 100mg/ml, injection, 10ml            |                           | Each | 412,200    |
| 157     | Vitamin B12 (Cyanocobalamin) 1000mcg, injection, 1ml       |                           | Each | 487,350    |
| 158     | Vitamin K1 (Phytomenadione) 10mg/1ml, injection            |                           | Each | 773,990    |
| 159     | Vitamin K1 (Phytomenadione) 2mg/0.2ml, injection           |                           | Each | 3,500,390  |
| 160     | Water for injection BP, injection, 10ml                    |                           | Each | 37,241,680 |
| 161     | Water for injection BP, injection, 20ml                    |                           | Each | 4,112,500  |
| 162     | Zuclopenthixol acetate 50mg, injection, 1ml                |                           | Each | 228,680    |
| 163     | Zuclopenthixol decanoate 200mg/ml, injection, 1ml          |                           | Each | 2,142,750  |